Avi Ashkenazi - Publications

Affiliations: 
Genentech, Inc., San Francisco, CA, United States 

377 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2021 Tran NH, Carter SD, De Mazière A, Ashkenazi A, Klumperman J, Walter P, Jensen GJ. The stress-sensing domain of activated IRE1α forms helical filaments in narrow ER membrane tubes. Science (New York, N.Y.). 374: 52-57. PMID 34591618 DOI: 10.1126/science.abh2474  1
2020 Beveridge RE, Wallweber HA, Ashkenazi A, Beresini M, Clark KR, Gibbons P, Ghiro E, Kaufman S, Larivée A, Leblanc M, Leclerc JP, Lemire A, Ly C, Rudolph J, Schwarz JB, et al. Identification of BRaf-Sparing Amino-Thienopyrimidines with Potent IRE1α Inhibitory Activity. Acs Medicinal Chemistry Letters. 11: 2389-2396. PMID 33335661 DOI: 10.1021/acsmedchemlett.0c00344  1
2020 Ferri E, Le Thomas A, Wallweber HA, Day ES, Walters BT, Kaufman SE, Braun MG, Clark KR, Beresini MH, Mortara K, Chen YA, Canter B, Phung W, Liu PS, Lammens A, ... Ashkenazi A, et al. Activation of the IRE1 RNase through remodeling of the kinase front pocket by ATP-competitive ligands. Nature Communications. 11: 6387. PMID 33318494 DOI: 10.1038/s41467-020-19974-5  0.01
2020 Harnoss JM, Le Thomas A, Reichelt M, Guttman O, Wu TD, Marsters SA, Shemorry A, Lawrence DA, Kan D, Segal E, Merchant M, Totpal K, Crocker LM, Mesh K, Dohse M, ... ... Ashkenazi A, et al. IRE1α disruption in triple-negative breast cancer cooperates with anti-angiogenic therapy by reversing ER stress adaptation and remodeling the tumor microenvironment. Cancer Research. PMID 32265225 DOI: 10.1158/0008-5472.Can-19-3108  1
2020 Lam M, Marsters SA, Ashkenazi A, Walter P. Misfolded proteins bind and activate death receptor 5 to induce apoptosis during unresolved endoplasmic reticulum stress. Elife. 9. PMID 31904339 DOI: 10.7554/Elife.52291  1
2020 Abratenko P, Alrashed M, An R, Anthony J, Asaadi J, Ashkenazi A, Balasubramanian S, Baller B, Barnes C, Barr G, Basque V, Berkman S, Bhanderi A, Bhat A, Bishai M, et al. Search for heavy neutral leptons decaying into muon-pion pairs in the MicroBooNE detector Physical Review D. 101: 52001. DOI: 10.1103/Physrevd.101.052001  1
2020 Adams C, Alrashed M, An R, Anthony J, Asaadi J, Ashkenazi A, Balasubramanian S, Baller B, Barnes C, Barr G, Basque V, Bass M, Bay F, Berkman S, Bhanderi A, et al. A method to determine the electric field of liquid argon time projection chambers using a UV laser system and its application in MicroBooNE Journal of Instrumentation. 15: P07010-P07010. DOI: 10.1088/1748-0221/15/07/P07010  0.01
2020 Adams C, Alrashed M, An R, Anthony J, Asaadi J, Ashkenazi A, Balasubramanian S, Baller B, Barnes C, Barr G, Basque V, Bass M, Bay F, Berkman S, Bhanderi A, et al. Calibration of the charge and energy loss per unit length of the MicroBooNE liquid argon time projection chamber using muons and protons Journal of Instrumentation. 15: P03022-P03022. DOI: 10.1088/1748-0221/15/03/P03022  0.01
2020 Adams C, Alrashed M, An R, Anthony J, Asaadi J, Ashkenazi A, Balasubramanian S, Baller B, Barnes C, Barr G, Basque V, Bass M, Bay F, Berkman S, Bhanderi A, et al. Reconstruction and measurement of Journal of Instrumentation. 15: P02007-P02007. DOI: 10.1088/1748-0221/15/02/P02007  0.01
2019 Abratenko P, Adams C, Alrashed M, An R, Anthony J, Asaadi J, Ashkenazi A, Auger M, Balasubramanian S, Baller B, Barnes C, Barr G, Bass M, Bay F, Bhat A, et al. First Measurement of Inclusive Muon Neutrino Charged Current Differential Cross Sections on Argon at E_{ν}∼0.8  GeV with the MicroBooNE Detector. Physical Review Letters. 123: 131801. PMID 31697542 DOI: 10.1103/Physrevlett.123.131801  0.01
2019 Shemorry A, Harnoss JM, Guttman O, Marsters SA, Kőműves LG, Lawrence DA, Ashkenazi A. Caspase-mediated cleavage of IRE1 controls apoptotic cell commitment during endoplasmic reticulum stress. Elife. 8. PMID 31453810 DOI: 10.7554/Elife.47084  1
2019 Harnoss JM, Le Thomas A, Shemorry A, Marsters SA, Lawrence DA, Lu M, Chen YA, Qing J, Totpal K, Kan D, Segal E, Merchant M, Reichelt M, Ackerly Wallweber H, Wang W, ... ... Ashkenazi A, et al. Disruption of IRE1α through its kinase domain attenuates multiple myeloma. Proceedings of the National Academy of Sciences of the United States of America. PMID 31371506 DOI: 10.1073/Pnas.1906999116  1
2019 Yang Y, Yeh SH, Madireddi S, Matochko WL, Gu C, Pacheco Sanchez P, Ultsch M, de Leon Boenig G, Harris SF, Leonard B, Scales SJ, Zhu J, Christensen E, Hang JQ, Brezski RJ, ... ... Ashkenazi A, et al. Tetravalent biepitopic targeting enables intrinsic antibody agonism of tumor necrosis factor receptor superfamily members. Mabs. PMID 31156033 DOI: 10.1080/19420862.2019.1625662  1
2019 Lam M, Marsters SA, Ashkenazi A, Walter P. Author response: Misfolded proteins bind and activate death receptor 5 to trigger apoptosis during unresolved endoplasmic reticulum stress Elife. DOI: 10.7554/Elife.52291.Sa2  1
2019 Shemorry A, Harnoss JM, Guttman O, Marsters SA, Kőműves LG, Lawrence DA, Ashkenazi A. Author response: Caspase-mediated cleavage of IRE1 controls apoptotic cell commitment during endoplasmic reticulum stress Elife. DOI: 10.7554/Elife.47084.015  1
2019 Adams C, Alrashed M, An R, Anthony J, Asaadi J, Ashkenazi A, Auger M, Balasubramanian S, Baller B, Barnes C, Barr G, Bass M, Bay F, Bhat A, Bhattacharya K, et al. Rejecting cosmic background for exclusive charged current quasi elastic neutrino interaction studies with Liquid Argon TPCs; a case study with the MicroBooNE detector European Physical Journal C. 79: 673. DOI: 10.1140/Epjc/S10052-019-7184-7  1
2019 Adams C, Alrashed M, An R, Anthony J, Asaadi J, Ashkenazi A, Auger M, Balasubramanian S, Baller B, Barnes C, Barr G, Bass M, Bay F, Bhat A, Bhattacharya K, et al. Deep neural network for pixel-level electromagnetic particle identification in the MicroBooNE liquid argon time projection chamber Physical Review D. 99: 92001. DOI: 10.1103/Physrevd.99.092001  1
2019 Alrashed M, An R, Anthony J, Asaadi J, Ashkenazi A, Auger M, Balasubramanian S, Baller B, Barnes C, Barr G, Bass M, Bay F, Bhat A, Bhattacharya K, Bishai M, et al. First measurement of νμ charged-current π0 production on argon with the MicroBooNE detector Physical Review D. 99: 91102. DOI: 10.1103/Physrevd.99.091102  1
2019 Adams C, Alrashed M, An R, Anthony J, Asaadi J, Ashkenazi A, Auger M, Balasubramanian S, Baller B, Barnes C, Barr G, Bass M, Bay F, Bhat A, Bhattacharya K, et al. Design and construction of the MicroBooNE Cosmic Ray Tagger system Journal of Instrumentation. 14: P04004-P04004. DOI: 10.1088/1748-0221/14/04/P04004  0.01
2018 Chang TK, Lawrence DA, Lu M, Tan J, Harnoss JM, Marsters SA, Liu P, Sandoval W, Martin SE, Ashkenazi A. Coordination between Two Branches of the Unfolded Protein Response Determines Apoptotic Cell Fate. Molecular Cell. 71: 629-636.e5. PMID 30118681 DOI: 10.1016/J.Molcel.2018.06.038  1
2018 Duer M, Price JW, Arrington J, Amaryan MJ, Batourine V, Briscoe WJ, Rossi P, Khachatryan M, Niculescu G, Sanctis ED, Nadel-Turonski P, Wei X, Schmidt A, Joo K, Marchand C, ... ... Ashkenazi A, et al. Probing high-momentum protons and neutrons in neutron-rich nuclei Nature. 560: 617-621. PMID 30104596 DOI: 10.1038/S41586-018-0400-Z  0.01
2018 Lam M, Lawrence DA, Ashkenazi A, Walter P. Confirming a critical role for death receptor 5 and caspase-8 in apoptosis induction by endoplasmic reticulum stress. Cell Death and Differentiation. PMID 29991746 DOI: 10.1038/S41418-018-0155-Y  1
2017 Ashkenazi A, Fairbrother WJ, Leverson JD, Souers AJ. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors. Nature Reviews. Drug Discovery. PMID 28209992 DOI: 10.1038/Nrd.2016.253  1
2016 Zhou L, Ashkenazi A, Smith JW, Jen N, Deer TR, Zhou C. Long-Term Clinical Outcome of Peripheral Nerve Stimulation for Chronic Headache and Complication Prevention. Anesthesiology and Pain Medicine. 6: e35983. PMID 27843774 DOI: 10.5812/aapm.35983  1
2016 Zuch de Zafra CL, Ashkenazi A, Darbonne WC, Cheu M, Totpal K, Ortega S, Flores H, Walker MD, Kabakoff B, Lum BL, Mounho-Zamora BJ, Marsters SA, Dybdal NO. Antitherapeutic antibody-mediated hepatotoxicity of recombinant human Apo2L/TRAIL in the cynomolgus monkey. Cell Death & Disease. 7: e2338. PMID 27512959 DOI: 10.1038/Cddis.2016.241  1
2016 Anania VG, Yu K, Gnad F, Pferdehirt RR, Li H, Ma T, Jeon D, Fortelny N, Forrest W, Ashkenazi A, Overall CM, Lill JR. Uncovering a dual regulatory role for caspases during endoplasmic reticulum stress-induced cell death. Molecular & Cellular Proteomics : McP. PMID 27125827 DOI: 10.1074/Mcp.M115.055376  1
2016 Michelle Androulakis X, Krebs KA, Ashkenazi A. Hemicrania continua may respond to repetitive sphenopalatine ganglion block: A case report. Headache. PMID 26926875 DOI: 10.1111/head.12783  0.01
2015 Cheah CY, Belada D, Fanale MA, Janikova A, Czucman MS, Flinn IW, Kapp AV, Ashkenazi A, Kelley S, Bray GL, Holden S, Seymour JF. Dulanermin with rituximab in patients with relapsed indolent B-cell lymphoma: an open-label phase 1b/2 randomised study. The Lancet. Haematology. 2: e166-74. PMID 26687959 DOI: 10.1016/S2352-3026(15)00026-5  1
2015 Robbins MS, Robertson CE, Kaplan E, Ailani J, Charleston L, Kuruvilla D, Blumenfeld A, Berliner R, Rosen NL, Duarte R, Vidwan J, Halker RB, Gill N, Ashkenazi A. The Sphenopalatine Ganglion: Anatomy, Pathophysiology, and Therapeutic Targeting in Headache. Headache. PMID 26615983 DOI: 10.1111/head.12729  1
2015 Aad G, Abbott B, Abdallah J, Abdinov O, Aben R, Abolins M, AbouZeid OS, Abramowicz H, Abreu H, Abreu R, Abulaiti Y, Acharya BS, Adamczyk L, Adams DL, Adelman J, ... ... Ashkenazi A, et al. ATLAS Run 1 searches for direct pair production of third-generation squarks at the Large Hadron Collider. The European Physical Journal. C, Particles and Fields. 75: 510. PMID 26549981 DOI: 10.1140/Epjc/S10052-015-3726-9  0.01
2015 Aad G, Abbott B, Abdallah J, Abdinov O, Aben R, Abolins M, AbouZeid OS, Abramowicz H, Abreu H, Abreu R, Abulaiti Y, Acharya BS, Adamczyk L, Adams DL, ... ... Ashkenazi A, et al. Search for metastable heavy charged particles with large ionisation energy loss in pp collisions at [Formula: see text] TeV using the ATLAS experiment. The European Physical Journal. C, Particles and Fields. 75: 407. PMID 26543401 DOI: 10.1140/Epjc/S10052-015-3609-0  0.01
2015 Aad G, Abbott B, Abdallah J, Abdinov O, Aben R, Abolins M, AbouZeid OS, Abramowicz H, Abreu H, Abreu R, Abulaiti Y, Acharya BS, Adamczyk L, Adams DL, Adelman J, ... ... Ashkenazi A, et al. Study of the spin and parity of the Higgs boson in diboson decays with the ATLAS detector. The European Physical Journal. C, Particles and Fields. 75: 476. PMID 26472935 DOI: 10.1140/Epjc/S10052-015-3685-1  0.01
2015 Nair PM, Ngu H, Torres E, Marsters S, Lawrence DA, Stephan JP, Komuves L, Ashkenazi A. Membrane display and functional analysis of juxtacrine ligand-receptor signaling. Biotechniques. 59: 231-40. PMID 26458551 DOI: 10.2144/000114342  1
2015 Aad G, Abbott B, Abdallah J, Abdel Khalek S, Abdinov O, Aben R, Abi B, Abolins M, AbouZeid OS, Abramowicz H, Abreu H, Abreu R, Abulaiti Y, Acharya BS, Adamczyk L, ... ... Ashkenazi A, et al. Two-particle Bose-Einstein correlations in pp collisions at [Formula: see text] 0.9 and 7 TeV measured with the ATLAS detector. The European Physical Journal. C, Particles and Fields. 75: 466. PMID 26457062 DOI: 10.1140/Epjc/S10052-015-3644-X  0.01
2015 Aad G, Abbott B, Abdallah J, Abdinov O, Aben R, Abolins M, AbouZeid OS, Abramowicz H, Abreu H, Abreu R, Abulaiti Y, Acharya BS, Adamczyk L, Adams DL, Adelman J, ... ... Ashkenazi A, et al. Search for Dark Matter in Events with Missing Transverse Momentum and a Higgs Boson Decaying to Two Photons in pp Collisions at sqrt[s]=8 TeV with the ATLAS Detector. Physical Review Letters. 115: 131801. PMID 26451544 DOI: 10.1103/Physrevlett.115.131801  0.01
2015 Aad G, Abbott B, Abdallah J, Abdinov O, Aben R, Abolins M, AbouZeid OS, Abramowicz H, Abreu H, Abreu R, Abulaiti Y, Acharya BS, Adamczyk L, Adams DL, Adelman J, ... ... Ashkenazi A, et al. Search for Higgs boson pair production in the [Formula: see text] final state from pp collisions at [Formula: see text] TeVwith the ATLAS detector. The European Physical Journal. C, Particles and Fields. 75: 412. PMID 26380565 DOI: 10.1140/Epjc/S10052-015-3628-X  0.01
2015 Aad G, Abbott B, Abdallah J, Abdinov O, Aben R, Abolins M, AbouZeid OS, Abramowicz H, Abreu H, Abreu R, Abulaiti Y, Acharya BS, Adamczyk L, Adams DL, Adelman J, ... ... Ashkenazi A, et al. Measurements of the Total and Differential Higgs Boson Production Cross Sections Combining the H→γγ and H→ZZ^{*}→4ℓ Decay Channels at sqrt[s]=8  TeV with the ATLAS Detector. Physical Review Letters. 115: 091801. PMID 26371640 DOI: 10.1103/Physrevlett.115.091801  0.01
2015 Aad G, Abbott B, Abdallah J, Abdinov O, Aben R, Abolins M, AbouZeid OS, Abramowicz H, Abreu H, Abreu R, Abulaiti Y, Acharya BS, Adamczyk L, Adams DL, Adelman J, ... ... Ashkenazi A, et al. Search for heavy long-lived multi-charged particles in pp collisions at [Formula: see text] TeV using the ATLAS detector. The European Physical Journal. C, Particles and Fields. 75: 362. PMID 26300688 DOI: 10.1140/Epjc/S10052-015-3534-2  0.01
2015 Aad G, Abbott B, Abdallah J, Abdinov O, Aben R, Abolins M, AbouZeid OS, Abramowicz H, Abreu H, Abreu R, Abulaiti Y, Acharya BS, Adamczyk L, Adams DL, Adelman J, ... ... Ashkenazi A, et al. Search for the Standard Model Higgs boson produced in association with top quarks and decaying into [Formula: see text] in [Formula: see text] collisions at [Formula: see text] with the ATLAS detector. The European Physical Journal. C, Particles and Fields. 75: 349. PMID 26269691 DOI: 10.1140/Epjc/S10052-015-3543-1  0.01
2015 Yin Y, Djakovic S, Marsters S, Tien J, Peng J, Tremayne J, Lee G, Neve RM, Wu Y, Merchant M, Ashkenazi A, Carter PJ. Redesigning a Monospecific Anti-FGFR3 Antibody to Add Selectivity for FGFR2 and Expand Anti-tumor Activity. Molecular Cancer Therapeutics. PMID 26269606 DOI: 10.1158/1535-7163.Mct-14-1050  1
2015 Aad G, Abbott B, Abdallah J, Abdel Khalek S, Abdinov O, Aben R, Abi B, Abolins M, AbouZeid OS, Abramowicz H, Abreu H, Abreu R, Abulaiti Y, Acharya BS, Adamczyk L, ... ... Ashkenazi A, et al. Evidence of Wγγ Production in pp Collisions at sqrt[s]=8  TeV and Limits on Anomalous Quartic Gauge Couplings with the ATLAS Detector. Physical Review Letters. 115: 031802. PMID 26230784 DOI: 10.1103/Physrevlett.115.031802  0.01
2015 Aad G, Abbott B, Abdallah J, Abdinov O, Aben R, Abolins M, AbouZeid OS, Abramowicz H, Abreu H, Abreu R, Abulaiti Y, Acharya BS, Adamczyk L, Adams DL, Adelman J, ... ... Ashkenazi A, et al. Search for a Heavy Neutral Particle Decaying to eμ, eτ, or μτ in pp Collisions at sqrt[s]=8  TeV with the ATLAS Detector. Physical Review Letters. 115: 031801. PMID 26230783 DOI: 10.1103/Physrevlett.115.031801  0.01
2015 Aad G, Abbott B, Abdallah J, Abdinov O, Aben R, Abolins M, AbouZeid OS, Abramowicz H, Abreu H, Abreu R, Abulaiti Y, Acharya BS, Adamczyk L, Adams DL, Adelman J, ... ... Ashkenazi A, et al. Search for invisible decays of the Higgs boson produced in association with a hadronically decaying vector boson in pp collisions at [Formula: see text] TeV with the ATLAS detector. The European Physical Journal. C, Particles and Fields. 75: 337. PMID 26213489 DOI: 10.1140/Epjc/S10052-015-3551-1  0.01
2015 Aad G, Abbott B, Abdallah J, Abdinov O, Aben R, Abolins M, AbouZeid OS, Abramowicz H, Abreu H, Abreu R, Abulaiti Y, Acharya BS, Adamczyk L, Adams DL, ... ... Ashkenazi A, et al. Constraints on the off-shell Higgs boson signal strength in the high-mass ZZ and WW final states with the ATLAS detector. The European Physical Journal. C, Particles and Fields. 75: 335. PMID 26213488 DOI: 10.1140/Epjc/S10052-015-3542-2  0.01
2015 Aad G, Abbott B, Abdallah J, Abdinov O, Aben R, Abolins M, AbouZeid OS, Abramowicz H, Abreu H, Abreu R, Abulaiti Y, Acharya BS, Adamczyk L, Adams DL, ... ... Ashkenazi A, et al. Measurement of the top quark mass in the [Formula: see text] and [Formula: see text] channels using [Formula: see text] [Formula: see text] ATLAS data. The European Physical Journal. C, Particles and Fields. 75: 330. PMID 26213487 DOI: 10.1140/Epjc/S10052-015-3544-0  0.01
2015 Aad G, Abbott B, Abdallah J, Abdinov O, Aben R, Abolins M, AbouZeid OS, Abramowicz H, Abreu H, Abreu R, Abulaiti Y, Acharya BS, Adamczyk L, Adams DL, Adelman J, ... ... Ashkenazi A, et al. Search for a Charged Higgs Boson Produced in the Vector-Boson Fusion Mode with Decay H(±)→W(±)Z using pp Collisions at √s=8  TeV with the ATLAS Experiment. Physical Review Letters. 114: 231801. PMID 26196792 DOI: 10.1103/Physrevlett.114.231801  0.01
2015 Aad G, Abbott B, Abdallah J, Abdinov O, Aben R, Abolins M, AbouZeid OS, Abramowicz H, Abreu H, Abreu R, Abulaiti Y, Acharya BS, Adamczyk L, Adams DL, Adelman J, ... ... Ashkenazi A, et al. Search for New Phenomena in Dijet Angular Distributions in Proton-Proton Collisions at sqrt[s]=8 TeV Measured with the ATLAS Detector. Physical Review Letters. 114: 221802. PMID 26196615 DOI: 10.1103/Physrevlett.114.221802  0.01
2015 Aad G, Abbott B, Abdallah J, Abdinov O, Aben R, Abolins M, AbouZeid OS, Abramowicz H, Abreu H, Abreu R, Abulaiti Y, Acharya BS, Adamczyk L, Adams DL, Adelman J, ... ... Ashkenazi A, et al. Search for supersymmetry in events containing a same-flavour opposite-sign dilepton pair, jets, and large missing transverse momentum in [Formula: see text] TeV pp collisions with the ATLAS detector. The European Physical Journal. C, Particles and Fields. 75: 318. PMID 26190940 DOI: 10.1140/Epjc/S10052-015-3518-2  0.01
2015 Aad G, Abbott B, Abdallah J, Abdel Khalek S, Abdinov O, Aben R, Abi B, Abolins M, AbouZeid OS, Abramowicz H, Abreu H, Abreu R, Abulaiti Y, Acharya BS, Adamczyk L, ... ... Ashkenazi A, et al. Identification and energy calibration of hadronically decaying tau leptons with the ATLAS experiment in pp collisions at [Formula: see text][Formula: see text]. The European Physical Journal. C, Particles and Fields. 75: 303. PMID 26190938 DOI: 10.1140/Epjc/S10052-015-3500-Z  0.01
2015 Aad G, Abbott B, Abdallah J, Abdel Khalek S, Abdinov O, Aben R, Abi B, Abolins M, AbouZeid OS, Abramowicz H, Abreu H, Abreu R, Abulaiti Y, Acharya BS, Adamczyk L, ... ... Ashkenazi A, et al. Search for new phenomena in final states with an energetic jet and large missing transverse momentum in pp collisions at [Formula: see text]TeV with the ATLAS detector. The European Physical Journal. C, Particles and Fields. 75: 299. PMID 26190936 DOI: 10.1140/Epjc/S10052-015-3517-3  0.01
2015 Chen TT, Filvaroff E, Peng J, Marsters S, Jubb A, Koeppen H, Merchant M, Ashkenazi A. MET Suppresses Epithelial VEGFR2 via Intracrine VEGF-induced Endoplasmic Reticulum-associated Degradation. Ebiomedicine. 2: 406-20. PMID 26137585 DOI: 10.1016/J.Ebiom.2015.03.021  1
2015 Aad G, Abbott B, Abdallah J, Abdinov O, Aben R, Abolins M, AbouZeid OS, Abramowicz H, Abreu H, Abreu R, Abulaiti Y, Acharya BS, Adamczyk L, Adams DL, Adelman J, ... ... Ashkenazi A, et al. Search for a new resonance decaying to a W or Z boson and a Higgs boson in the [Formula: see text] final states with the ATLAS detector. The European Physical Journal. C, Particles and Fields. 75: 263. PMID 26097411 DOI: 10.1140/Epjc/S10052-015-3474-X  0.01
2015 Aad G, Abbott B, Abdallah J, Abdinov O, Aben R, Abolins M, AbouZeid OS, Abramowicz H, Abreu H, Abreu R, Abulaiti Y, Acharya BS, Adamczyk L, Adams DL, ... ... Ashkenazi A, et al. Determination of spin and parity of the Higgs boson in the [Formula: see text] decay channel with the ATLAS detector. The European Physical Journal. C, Particles and Fields. 75: 231. PMID 26041978 DOI: 10.1140/Epjc/S10052-015-3436-3  0.01
2015 Aad G, Abbott B, Abdallah J, Abdel Khalek S, Abdinov O, Aben R, Abi B, Abolins M, AbouZeid OS, Abramowicz H, Abreu H, Abreu R, Abulaiti Y, Acharya BS, Adamczyk L, ... ... Ashkenazi A, et al. Observation and measurements of the production of prompt and non-prompt [Formula: see text] mesons in association with a [Formula: see text] boson in [Formula: see text] collisions at [Formula: see text] with the ATLAS detector. The European Physical Journal. C, Particles and Fields. 75: 229. PMID 26041977 DOI: 10.1140/Epjc/S10052-015-3406-9  0.01
2015 Aad G, Abbott B, Abdallah J, Abdel Khalek S, Abdinov O, Aben R, Abi B, Abolins M, AbouZeid OS, Abramowicz H, Abreu H, Abreu R, Abulaiti Y, Acharya BS, ... ... Ashkenazi A, et al. Measurement of three-jet production cross-sections in [Formula: see text] collisions at 7 [Formula: see text] centre-of-mass energy using the ATLAS detector. The European Physical Journal. C, Particles and Fields. 75: 228. PMID 26041976 DOI: 10.1140/Epjc/S10052-015-3363-3  0.01
2015 Aad G, Abbott B, Abdallah J, Abdel Khalek S, Abdinov O, Aben R, Abi B, Abolins M, AbouZeid OS, Abramowicz H, Abreu H, Abreu R, Abulaiti Y, Acharya BS, ... ... Ashkenazi A, et al. Measurement of the top-quark mass in the fully hadronic decay channel from ATLAS data at [Formula: see text]. The European Physical Journal. C, Particles and Fields. 75: 158. PMID 26041974 DOI: 10.1140/Epjc/S10052-015-3373-1  0.01
2015 Aad G, Abbott B, Abdallah J, Abdinov O, Aben R, Abolins M, AbouZeid OS, Abramowicz H, Abreu H, Abreu R, Abulaiti Y, Acharya BS, Adamczyk L, Adams DL, Adelman J, ... ... Ashkenazi A, et al. Combined Measurement of the Higgs Boson Mass in pp Collisions at sqrt[s]=7 and 8 TeV with the ATLAS and CMS Experiments. Physical Review Letters. 114: 191803. PMID 26024162 DOI: 10.1103/Physrevlett.114.191803  0.01
2015 Aad G, Abbott B, Abdallah J, Abdel Khalek S, Abdinov O, Aben R, Abi B, Abolins M, AbouZeid OS, Abramowicz H, Abreu H, Abreu R, Abulaiti Y, Acharya BS, Adamczyk L, ... ... Ashkenazi A, et al. Search for production of [Formula: see text] resonances decaying to a lepton, neutrino and jets in [Formula: see text] collisions at [Formula: see text] TeV with the ATLAS detector. The European Physical Journal. C, Particles and Fields. 75: 209. PMID 25995709 DOI: 10.1140/Epjc/S10052-015-3425-6  0.01
2015 Aad G, Abbott B, Abdallah J, Abdel Khalek S, Abdinov O, Aben R, Abi B, Abolins M, AbouZeid OS, Abramowicz H, Abreu H, Abreu R, Abulaiti Y, Acharya BS, Adamczyk L, ... ... Ashkenazi A, et al. Search for direct pair production of a chargino and a neutralino decaying to the 125 GeV Higgs boson in [Formula: see text] TeV [Formula: see text] collisions with the ATLAS detector. The European Physical Journal. C, Particles and Fields. 75: 208. PMID 25995708 DOI: 10.1140/Epjc/S10052-015-3408-7  0.01
2015 Aad G, Abbott B, Abdallah J, Abdel Khalek S, Abdinov O, Aben R, Abi B, Abolins M, AbouZeid OS, Abramowicz H, Abreu H, Abreu R, Abulaiti Y, Acharya BS, ... ... Ashkenazi A, et al. Measurement of the production and lepton charge asymmetry of [Formula: see text] bosons in Pb+Pb collisions at [Formula: see text] with the ATLAS detector. The European Physical Journal. C, Particles and Fields. 75: 23. PMID 25983646 DOI: 10.1140/Epjc/S10052-014-3231-6  0.01
2015 Aad G, Abbott B, Abdallah J, Abdel Khalek S, Abdinov O, Aben R, Abi B, Abolins M, AbouZeid OS, Abramowicz H, Abreu H, Abreu R, Abulaiti Y, Acharya BS, Adamczyk L, ... ... Ashkenazi A, et al. Search for Scalar Charm Quark Pair Production in pp Collisions at sqrt[s]=8  TeV with the ATLAS Detector. Physical Review Letters. 114: 161801. PMID 25955046 DOI: 10.1103/Physrevlett.114.161801  0.01
2015 Aad G, Abbott B, Abdallah J, Abdel Khalek S, Abdinov O, Aben R, Abi B, Abolins M, AbouZeid OS, Abramowicz H, Abreu H, Abreu R, Abulaiti Y, Acharya BS, ... ... Ashkenazi A, et al. Search for [Formula: see text] decays in [Formula: see text] collisions at [Formula: see text] = 8 TeV with the ATLAS detector. The European Physical Journal. C, Particles and Fields. 75: 165. PMID 25937816 DOI: 10.1140/Epjc/S10052-015-3372-2  0.01
2015 Blumenfeld A, Ashkenazi A, Evans RW. Occipital and trigeminal nerve blocks for migraine. Headache. 55: 682-9. PMID 25918869 DOI: 10.1111/head.12579  1
2015 Aad G, Abbott B, Abdallah J, Abdel Khalek S, Abdinov O, Aben R, Abi B, Abolins M, AbouZeid OS, Abramowicz H, Abreu H, Abreu R, Abulaiti Y, Acharya BS, Adamczyk L, ... ... Ashkenazi A, et al. Measurement of spin correlation in top-antitop quark events and search for top squark pair production in pp collisions at √s=8  TeV using the ATLAS detector. Physical Review Letters. 114: 142001. PMID 25910111 DOI: 10.1103/Physrevlett.114.142001  1
2015 Nair PM, Flores H, Gogineni A, Marsters S, Lawrence DA, Kelley RF, Ngu H, Sagolla M, Komuves L, Bourgon R, Settleman J, Ashkenazi A. Enhancing the antitumor efficacy of a cell-surface death ligand by covalent membrane display. Proceedings of the National Academy of Sciences of the United States of America. 112: 5679-84. PMID 25902490 DOI: 10.1073/Pnas.1418962112  1
2015 Petersen SL, Chen TT, Lawrence DA, Marsters SA, Gonzalvez F, Ashkenazi A. TRAF2 is a biologically important necroptosis suppressor. Cell Death and Differentiation. PMID 25882049 DOI: 10.1038/Cdd.2015.35  1
2015 Aad G, Abbott B, Abdallah J, Abdel Khalek S, Abdinov O, Aben R, Abi B, Abolins M, AbouZeid OS, Abramowicz H, Abreu H, Abreu R, Abulaiti Y, Acharya BS, Adamczyk L, ... ... Ashkenazi A, et al. Search for Higgs and Z Boson Decays to J/ψγ and ϒ(nS)γ with the ATLAS Detector. Physical Review Letters. 114: 121801. PMID 25860734 DOI: 10.1103/Physrevlett.114.121801  0.01
2015 Aad G, Abbott B, Abdallah J, Abdel Khalek S, Abdinov O, Aben R, Abi B, Abolins M, AbouZeid OS, Abramowicz H, Abreu H, Abreu R, Abulaiti Y, Acharya BS, ... ... Ashkenazi A, et al. Performance of the ATLAS muon trigger in pp collisions at [Formula: see text] TeV. The European Physical Journal. C, Particles and Fields. 75: 120. PMID 25838797 DOI: 10.1140/Epjc/S10052-015-3325-9  0.01
2015 Aad G, Abbott B, Abdallah J, Abdel Khalek S, Abdinov O, Aben R, Abi B, Abolins M, AbouZeid OS, Abramowicz H, Abreu H, Abreu R, Abulaiti Y, Acharya BS, ... ... Ashkenazi A, et al. Search for dark matter in events with heavy quarks and missing transverse momentum in [Formula: see text] collisions with the ATLAS detector. The European Physical Journal. C, Particles and Fields. 75: 92. PMID 25838796 DOI: 10.1140/Epjc/S10052-015-3306-Z  0.01
2015 Aad G, Abbott B, Abdallah J, Abdel Khalek S, Abdinov O, Aben R, Abi B, Abolins M, AbouZeid OS, Abramowicz H, Abreu H, Abreu R, Abulaiti Y, Acharya BS, ... ... Ashkenazi A, et al. Measurements of the [Formula: see text] production cross sections in association with jets with the ATLAS detector. The European Physical Journal. C, Particles and Fields. 75: 82. PMID 25838794 DOI: 10.1140/Epjc/S10052-015-3262-7  0.01
2015 Aad G, Abbott B, Abdallah J, Abdel Khalek S, Abdinov O, Aben R, Abi B, Abolins M, AbouZeid OS, Abramowicz H, Abreu H, Abreu R, Abulaiti Y, Acharya BS, ... ... Ashkenazi A, et al. Search for invisible particles produced in association with single-top-quarks in proton-proton collisions at [Formula: see text] with the ATLAS detector. The European Physical Journal. C, Particles and Fields. 75: 79. PMID 25838793 DOI: 10.1140/Epjc/S10052-014-3233-4  0.01
2015 Aad G, Abbott B, Abdallah J, Abdel Khalek S, Abdinov O, Aben R, Abi B, Abolins M, AbouZeid OS, Abramowicz H, Abreu H, Abreu R, Abulaiti Y, Acharya BS, ... ... Ashkenazi A, et al. Search for resonant diboson production in the [Formula: see text] final state in [Formula: see text] collisions at [Formula: see text] TeV with the ATLAS detector. The European Physical Journal. C, Particles and Fields. 75: 69. PMID 25838792 DOI: 10.1140/Epjc/S10052-015-3261-8  0.01
2015 Aad G, Abbott B, Abdallah J, Abdel Khalek S, Abdinov O, Aben R, Abi B, Abolins M, AbouZeid OS, Abramowicz H, Abreu H, Abreu R, Abulaiti Y, Acharya BS, Adamczyk L, ... ... Ashkenazi A, et al. Search for Higgs boson pair production in the γγbb[over ¯] final state using pp collision data at sqrt[s]=8  TeV from the ATLAS detector. Physical Review Letters. 114: 081802. PMID 25768755 DOI: 10.1103/Physrevlett.114.081802  0.01
2015 Aad G, Abbott B, Abdallah J, Abdel Khalek S, Abdinov O, Aben R, Abi B, Abolins M, AbouZeid OS, Abramowicz H, Abreu H, Abreu R, Abulaiti Y, Acharya BS, Adamczyk L, ... ... Ashkenazi A, et al. Measurements of the Nuclear Modification Factor for Jets in Pb+Pb Collisions at √(s)NN]=2.76  TeV with the ATLAS detector. Physical Review Letters. 114: 072302. PMID 25763955 DOI: 10.1103/Physrevlett.114.072302  0.01
2015 Ashkenazi A. Targeting the extrinsic apoptotic pathway in cancer: lessons learned and future directions. The Journal of Clinical Investigation. 125: 487-9. PMID 25642709 DOI: 10.1172/Jci80420  0.01
2015 Vicinanza M, Korolchuk VI, Ashkenazi A, Puri C, Menzies FM, Clarke JH, Rubinsztein DC. PI(5)P regulates autophagosome biogenesis. Molecular Cell. 57: 219-34. PMID 25578879 DOI: 10.1016/j.molcel.2014.12.007  0.01
2014 Aad G, Abbott B, Abdallah J, Abdel Khalek S, Abdinov O, Aben R, Abi B, Abolins M, AbouZeid OS, Abramowicz H, Abreu H, Abreu R, Abulaiti Y, Acharya BS, ... ... Ashkenazi A, et al. Measurement of distributions sensitive to the underlying event in inclusive Z-boson production in [Formula: see text] collisions at [Formula: see text] TeV with the ATLAS detector. The European Physical Journal. C, Particles and Fields. 74: 3195. PMID 25983639 DOI: 10.1140/Epjc/S10052-014-3195-6  0.01
2014 Aad G, Abbott B, Abdallah J, Abdel Khalek S, Abdinov O, Aben R, Abi B, Abolins M, AbouZeid OS, Abramowicz H, Abreu H, Abreu R, Abulaiti Y, Acharya BS, ... ... Ashkenazi A, et al. A measurement of the ratio of the production cross sections for [Formula: see text] and [Formula: see text] bosons in association with jets with the ATLAS detector. The European Physical Journal. C, Particles and Fields. 74: 3168. PMID 25983636 DOI: 10.1140/Epjc/S10052-014-3168-9  0.01
2014 Aad G, Abbott B, Abdallah J, Abdel Khalek S, Abdinov O, Aben R, Abi B, Abolins M, AbouZeid OS, Abramowicz H, Abreu H, Abreu R, Abulaiti Y, Acharya BS, ... ... Ashkenazi A, et al. Search for contact interactions and large extra dimensions in the dilepton channel using proton-proton collisions at [Formula: see text] 8 TeV with the ATLAS detector. The European Physical Journal. C, Particles and Fields. 74: 3134. PMID 25983635 DOI: 10.1140/Epjc/S10052-014-3134-6  0.01
2014 Aad G, Abbott B, Abdallah J, Abdel Khalek S, Abdinov O, Aben R, Abi B, Abolins M, AbouZeid OS, Abramowicz H, Abreu H, Abreu R, Abulaiti Y, Acharya BS, Adamczyk L, ... ... Ashkenazi A, et al. Light-quark and gluon jet discrimination in [Formula: see text] collisions at [Formula: see text] with the ATLAS detector. The European Physical Journal. C, Particles and Fields. 74: 3023. PMID 25814910 DOI: 10.1140/Epjc/S10052-014-3023-Z  0.01
2014 Aad G, Abbott B, Abdallah J, Abdel Khalek S, Abdinov O, Aben R, Abi B, Abolins M, AbouZeid OS, Abramowicz H, Abreu H, Abreu R, Abulaiti Y, Acharya BS, ... ... Ashkenazi A, et al. Measurement of the centrality and pseudorapidity dependence of the integrated elliptic flow in lead-lead collisions at [Formula: see text] TeV with the ATLAS detector. The European Physical Journal. C, Particles and Fields. 74: 2982. PMID 25814907 DOI: 10.1140/Epjc/S10052-014-2982-4  0.01
2014 Aad G, Abajyan T, Abbott B, Abdallah J, Khalek SA, Abdinov O, Aben R, Abi B, Abolins M, AbouZeid OS, Abramowicz H, Abreu H, Abulaiti Y, Acharya BS, ... ... Ashkenazi A, et al. Electron reconstruction and identification efficiency measurements with the ATLAS detector using the 2011 LHC proton-proton collision data. The European Physical Journal. C, Particles and Fields. 74: 2941. PMID 25814900 DOI: 10.1140/Epjc/S10052-014-2941-0  0.01
2014 Aad G, Abbott B, Abdallah J, Khalek SA, Abdinov O, Aben R, Abi B, Abolins M, AbouZeid OS, Abramowicz H, Abreu H, Abreu R, Abulaiti Y, Acharya BS, ... ... Ashkenazi A, et al. Search for direct top squark pair production in events with a [Formula: see text] boson, [Formula: see text]-jets and missing transverse momentum in [Formula: see text] TeV [Formula: see text] collisions with the ATLAS detector. The European Physical Journal. C, Particles and Fields. 74: 2883. PMID 25814893 DOI: 10.1140/Epjc/S10052-014-2883-6  0.01
2014 Aad G, Abbott B, Abdallah J, Abdel Khalek S, Abdinov O, Aben R, Abi B, Abolins M, AbouZeid OS, Abramowicz H, Abreu H, Abreu R, Abulaiti Y, Acharya BS, ... ... Ashkenazi A, et al. Measurement of flow harmonics with multi-particle cumulants in Pb+Pb collisions at [Formula: see text] TeV with the ATLAS detector. The European Physical Journal. C, Particles and Fields. 74: 3157. PMID 25814877 DOI: 10.1140/Epjc/S10052-014-3157-Z  0.01
2014 Aad G, Abbott B, Abdallah J, Abdel Khalek S, Abdinov O, Aben R, Abi B, Abolins M, AbouZeid OS, Abramowicz H, Abreu H, Abreu R, Abulaiti Y, Acharya BS, ... ... Ashkenazi A, et al. Measurement of the muon reconstruction performance of the ATLAS detector using 2011 and 2012 LHC proton-proton collision data. The European Physical Journal. C, Particles and Fields. 74: 3130. PMID 25814875 DOI: 10.1140/Epjc/S10052-014-3130-X  0.01
2014 Aad G, Abbott B, Abdallah J, Abdel Khalek S, Abdinov O, Aben R, Abi B, Abolins M, AbouZeid OS, Abramowicz H, Abreu H, Abreu R, Abulaiti Y, Acharya BS, ... ... Ashkenazi A, et al. Measurements of jet vetoes and azimuthal decorrelations in dijet events produced in [Formula: see text] collisions at [Formula: see text] using the ATLAS detector. The European Physical Journal. C, Particles and Fields. 74: 3117. PMID 25814873 DOI: 10.1140/Epjc/S10052-014-3117-7  0.01
2014 Aad G, Abbott B, Abdallah J, Abdel Khalek S, Abdinov O, Aben R, Abi B, Abolins M, AbouZeid OS, Abramowicz H, Abreu H, Abreu R, Abulaiti Y, Acharya BS, Adamczyk L, ... ... Ashkenazi A, et al. Measurement of the [Formula: see text] production cross-section using [Formula: see text] events with [Formula: see text]-tagged jets in [Formula: see text] collisions at [Formula: see text] and 8 TeV with the ATLAS detector. The European Physical Journal. C, Particles and Fields. 74: 3109. PMID 25814872 DOI: 10.1140/Epjc/S10052-014-3109-7  0.01
2014 Aad G, Abbott B, Abdallah J, Abdel Khalek S, Abdinov O, Aben R, Abi B, Abolins M, AbouZeid OS, Abramowicz H, Abreu H, Abreu R, Abulaiti Y, Acharya BS, Adamczyk L, ... ... Ashkenazi A, et al. Observation of an excited Bc(±) meson state with the ATLAS detector. Physical Review Letters. 113: 212004. PMID 25479491 DOI: 10.1103/Physrevlett.113.212004  0.01
2014 Aad G, Abbott B, Abdallah J, Abdel Khalek S, Abdinov O, Aben R, Abi B, Abolins M, AbouZeid OS, Abramowicz H, Abreu H, Abreu R, Abulaiti Y, Acharya BS, Adamczyk L, ... ... Ashkenazi A, et al. Search for scalar diphoton resonances in the mass range 65-600 GeV with the ATLAS detector in pp collision data at √s=8 TeV. Physical Review Letters. 113: 171801. PMID 25379911 DOI: 10.1103/Physrevlett.113.171801  0.01
2014 Du X, Lin BC, Wang QR, Li H, Ingalla E, Tien J, Rooney I, Ashkenazi A, Penuel E, Qing J. MMP-1 and Pro-MMP-10 as potential urinary pharmacodynamic biomarkers of FGFR3-targeted therapy in patients with bladder cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 6324-35. PMID 25326231 DOI: 10.1158/1078-0432.Ccr-13-3336  1
2014 Aad G, Abbott B, Abdallah J, Abdel Khalek S, Abdinov O, Aben R, Abi B, Abolins M, AbouZeid OS, Abramowicz H, Abreu H, Abreu R, Abulaiti Y, Acharya BS, Adamczyk L, ... ... Ashkenazi A, et al. Evidence for electroweak production of W±W±jj in pp collisions at sqrt[s] = 8 TeV with the ATLAS detector. Physical Review Letters. 113: 141803. PMID 25325632 DOI: 10.1103/Physrevlett.113.141803  0.01
2014 Robbins MS, Kuruvilla D, Blumenfeld A, Charleston L, Sorrell M, Robertson CE, Grosberg BM, Bender SD, Napchan U, Ashkenazi A. Trigger point injections for headache disorders: expert consensus methodology and narrative review. Headache. 54: 1441-59. PMID 25168295 DOI: 10.1111/head.12442  1
2014 Ashkenazi A, Salvesen G. Regulated cell death: signaling and mechanisms. Annual Review of Cell and Developmental Biology. 30: 337-56. PMID 25150011 DOI: 10.1146/Annurev-Cellbio-100913-013226  0.01
2014 Wilson C, Ye X, Pham T, Lin E, Chan S, McNamara E, Neve RM, Belmont L, Koeppen H, Yauch RL, Ashkenazi A, Settleman J. AXL inhibition sensitizes mesenchymal cancer cells to antimitotic drugs. Cancer Research. 74: 5878-90. PMID 25125659 DOI: 10.1158/0008-5472.Can-14-1009  1
2014 Ashkenazi A, Wells JA, Yuan J. Methods in Enzymology. Regulated cell death part B--necroptotic, autophagic and other non-apoptotic mechanisms. Preface. Methods in Enzymology. 545: xiii. PMID 25065895 DOI: 10.1016/B978-0-12-801430-1.10000-9  1
2014 Lu M, Lawrence DA, Marsters S, Acosta-Alvear D, Kimmig P, Mendez AS, Paton AW, Paton JC, Walter P, Ashkenazi A. Cell death. Opposing unfolded-protein-response signals converge on death receptor 5 to control apoptosis. Science (New York, N.Y.). 345: 98-101. PMID 24994655 DOI: 10.1126/Science.1254312  1
2014 Ashkenazi A, Yuan J, Wells JA. Regulated cell death part A: apoptotic mechanisms. Preface. Methods in Enzymology. 544: xv. PMID 24974300 DOI: 10.1016/B978-0-12-417158-9.10000-7  1
2014 Nair P, Lu M, Petersen S, Ashkenazi A. Apoptosis initiation through the cell-extrinsic pathway. Methods in Enzymology. 544: 99-128. PMID 24974288 DOI: 10.1016/B978-0-12-417158-9.00005-4  1
2014 Aad G, Abbott B, Abdallah J, Abdel Khalek S, Abdinov O, Aben R, Abi B, Abolins M, AbouZeid OS, Abramowicz H, Abreu H, Abreu R, Abulaiti Y, Acharya BS, Adamczyk L, ... ... Ashkenazi A, et al. Measurements of four-lepton production at the Z resonance in pp collisions at sqrt[s] = 7 and 8 TeV with ATLAS. Physical Review Letters. 112: 231806. PMID 24972200 DOI: 10.1103/Physrevlett.112.231806  0.01
2014 Fairbrother WJ, Ashkenazi A. Designer proteins to trigger cell death. Cell. 157: 1506-8. PMID 24949963 DOI: 10.1016/J.Cell.2014.06.010  1
2014 Lu M, Marsters S, Ye X, Luis E, Gonzalez L, Ashkenazi A. E-cadherin couples death receptors to the cytoskeleton to regulate apoptosis. Molecular Cell. 54: 987-98. PMID 24882208 DOI: 10.1016/J.Molcel.2014.04.029  1
2014 Klug YA, Ashkenazi A, Viard M, Porat Z, Blumenthal R, Shai Y. Early and late HIV-1 membrane fusion events are impaired by sphinganine lipidated peptides that target the fusion site. The Biochemical Journal. 461: 213-22. PMID 24766462 DOI: 10.1042/Bj20140189  1
2014 Wilson NS, Duewell P, Yang B, Li Y, Marsters S, Koernig S, Latz E, Maraskovsky E, Morelli AB, Schnurr M, Ashkenazi A. Inflammasome-dependent and -independent IL-18 production mediates immunity to the ISCOMATRIX adjuvant. Journal of Immunology (Baltimore, Md. : 1950). 192: 3259-68. PMID 24610009 DOI: 10.4049/Jimmunol.1302011  1
2014 Newton K, Hildebrand JM, Shen Z, Rodriguez D, Alvarez-Diaz S, Petersen S, Shah S, Dugger DL, Huang C, Auwerx J, Vandenabeele P, Green DR, Ashkenazi A, Dixit VM, Kaiser WJ, et al. Is SIRT2 required for necroptosis? Nature. 506: E4-6. PMID 24572428 DOI: 10.1038/Nature13024  1
2014 Wilson C, Pham T, Ye X, Lin E, Chan S, McNamara E, Neve RM, Belmont L, Koeppen H, Yauch RL, Ashkenazi A, Settleman J. Abstract 693: AXL tyrosine kinase inhibition selectively sensitizes mesenchymal cancer cells to antimitotic agents Cancer Research. 74: 693-693. DOI: 10.1158/1538-7445.Am2014-693  1
2014 Lin BC, Du X, Wang Q, Li H, Ingalla E, Tien J, Rooney I, Ashkenazi A, Penuel E, Qing J. Abstract 3690: MMP-1 and pro-MMP-10 as potential urinary pharmacodynamic biomarkers of FGFR3-targeted therapy in patients with bladder cancer Cancer Research. 74: 3690-3690. DOI: 10.1158/1538-7445.Am2014-3690  1
2013 Faingold O, Ashkenazi A, Kaushansky N, Ben-Nun A, Shai Y. An immunomodulating motif of the HIV-1 fusion protein is chirality-independent: implications for its mode of action. The Journal of Biological Chemistry. 288: 32852-60. PMID 24078631 DOI: 10.1074/Jbc.M113.512038  1
2013 Wainberg ZA, Messersmith WA, Peddi PF, Kapp AV, Ashkenazi A, Royer-Joo S, Portera CC, Kozloff MF. A phase 1B study of dulanermin in combination with modified FOLFOX6 plus bevacizumab in patients with metastatic colorectal cancer. Clinical Colorectal Cancer. 12: 248-54. PMID 24075777 DOI: 10.1016/J.Clcc.2013.06.002  1
2013 Ashkenazi A, Blumenfeld A. OnabotulinumtoxinA for the treatment of headache. Headache. 53: 54-61. PMID 24024603 DOI: 10.1111/head.12185  1
2013 Saar-Dover R, Ashkenazi A, Shai Y. Peptide interaction with and insertion into membranes. Methods in Molecular Biology (Clifton, N.J.). 1033: 173-83. PMID 23996178 DOI: 10.1007/978-1-62703-487-6_12  1
2013 Kim JM, Ashkenazi A. Fcγ receptors enable anticancer action of proapoptotic and immune-modulatory antibodies. The Journal of Experimental Medicine. 210: 1647-51. PMID 23980122 DOI: 10.1084/jem.20131625  0.01
2013 Qiu J, Ashkenazi A, Liu S, Shai Y. Structural and functional properties of the membranotropic HIV-1 glycoprotein gp41 loop region are modulated by its intrinsic hydrophobic core. The Journal of Biological Chemistry. 288: 29143-50. PMID 23960077 DOI: 10.1074/Jbc.M113.496646  1
2013 Chaudhuri A, Wilson NS, Yang B, Paler Martinez A, Liu J, Zhu C, Bricker N, Couto S, Modrusan Z, French D, Cupp J, Ashkenazi A. Host genetic background impacts modulation of the TLR4 pathway by RON in tissue-associated macrophages. Immunology and Cell Biology. 91: 451-60. PMID 23817579 DOI: 10.1038/Icb.2013.27  1
2013 Lim B, Scicchitano A, Beachler C, Gusani N, Sarwani N, Yang Z, Staveley-O'Carroll K, Ashkenazi A, Portera C, El-Deiry WS. FOLFIRI plus dulanermin (rhApo2L/TRAIL) in a patient with BRAF-mutant metastatic colon cancer. Cancer Biology & Therapy. 14: 711-9. PMID 23792567 DOI: 10.4161/Cbt.25310  0.01
2013 Sidrauski C, Acosta-Alvear D, Khoutorsky A, Vedantham P, Hearn BR, Li H, Gamache K, Gallagher CM, Ang KK, Wilson C, Okreglak V, Ashkenazi A, Hann B, Nader K, Arkin MR, et al. Pharmacological brake-release of mRNA translation enhances cognitive memory. Elife. 2: e00498. PMID 23741617 DOI: 10.7554/Elife.00498  1
2013 Ashkenazi A, Faingold O, Shai Y. HIV-1 fusion protein exerts complex immunosuppressive effects. Trends in Biochemical Sciences. 38: 345-9. PMID 23685134 DOI: 10.1016/J.Tibs.2013.04.003  1
2013 Gust KM, McConkey DJ, Awrey S, Hegarty PK, Qing J, Bondaruk J, Ashkenazi A, Czerniak B, Dinney CP, Black PC. Fibroblast growth factor receptor 3 is a rational therapeutic target in bladder cancer. Molecular Cancer Therapeutics. 12: 1245-54. PMID 23657946 DOI: 10.1158/1535-7163.Mct-12-1150  1
2013 Blumenfeld A, Ashkenazi A, Napchan U, Bender SD, Klein BC, Berliner R, Ailani J, Schim J, Friedman DI, Charleston L, Young WB, Robertson CE, Dodick DW, Silberstein SD, Robbins MS. Expert consensus recommendations for the performance of peripheral nerve blocks for headaches--a narrative review. Headache. 53: 437-46. PMID 23406160 DOI: 10.1111/head.12053  1
2013 Ashkenazi A, Faingold O, Kaushansky N, Ben-Nun A, Shai Y. A highly conserved sequence associated with the HIV gp41 loop region is an immunomodulator of antigen-specific T cells in mice. Blood. 121: 2244-52. PMID 23325839 DOI: 10.1182/Blood-2012-11-468900  1
2013 Ogasawara A, Tinianow JN, Vanderbilt AN, Gill HS, Yee S, Flores JE, Williams SP, Ashkenazi A, Marik J. ImmunoPET imaging of phosphatidylserine in pro-apoptotic therapy treated tumor models. Nuclear Medicine and Biology. 40: 15-22. PMID 23062948 DOI: 10.1016/J.Nucmedbio.2012.09.001  1
2013 Sidrauski C, Acosta-Alvear D, Khoutorsky A, Vedantham P, Hearn BR, Li H, Gamache K, Gallagher CM, Ang KK, Wilson C, Okreglak V, Ashkenazi A, Hann B, Nader K, Arkin MR, et al. Author response: Pharmacological brake-release of mRNA translation enhances cognitive memory Elife. DOI: 10.7554/Elife.00498.019  1
2013 Ye X, Yue P, Patel R, Modrusan Z, Settleman J, Ashkenazi A, Yauch RL. Abstract 4463: Activation of FGFR signaling as a mechanism of acquired resistance to erlotinib in EGFR-mutant lung cancer associated with an EMT. Cancer Research. 73: 4463-4463. DOI: 10.1158/1538-7445.Am2013-4463  1
2012 Gonzalvez F, Lawrence D, Yang B, Yee S, Pitti R, Marsters S, Pham VC, Stephan JP, Lill J, Ashkenazi A. TRAF2 Sets a threshold for extrinsic apoptosis by tagging caspase-8 with a ubiquitin shutoff timer. Molecular Cell. 48: 888-99. PMID 23142077 DOI: 10.1016/J.Molcel.2012.09.031  1
2012 Du X, Wang QR, Chan E, Merchant M, Liu J, French D, Ashkenazi A, Qing J. FGFR3 stimulates stearoyl CoA desaturase 1 activity to promote bladder tumor growth. Cancer Research. 72: 5843-55. PMID 23019225 DOI: 10.1158/0008-5472.Can-12-1329  1
2012 Lew B, Stief P, Beliavski M, Ashkenazi A, Svitlica O, Khan A, Tarre S, de Beer D, Green M. Characterization of denitrifying granular sludge with and without the addition of external carbon source. Bioresource Technology. 124: 413-20. PMID 23010209 DOI: 10.1016/j.biortech.2012.08.049  0.01
2012 Subbiah V, Brown RE, Buryanek J, Trent J, Ashkenazi A, Herbst R, Kurzrock R. Targeting the apoptotic pathway in chondrosarcoma using recombinant human Apo2L/TRAIL (dulanermin), a dual proapoptotic receptor (DR4/DR5) agonist. Molecular Cancer Therapeutics. 11: 2541-6. PMID 22914439 DOI: 10.1158/1535-7163.Mct-12-0358  1
2012 Ashkenazi A, Merklinger E, Shai Y. Intramolecular interactions within the human immunodeficiency virus-1 gp41 loop region and their involvement in lipid merging. Biochemistry. 51: 6981-9. PMID 22894130 DOI: 10.1021/Bi300868F  1
2012 Ashkenazi A, Viard M, Unger L, Blumenthal R, Shai Y. Sphingopeptides: dihydrosphingosine-based fusion inhibitors against wild-type and enfuvirtide-resistant HIV-1. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 26: 4628-36. PMID 22872679 DOI: 10.1096/Fj.12-215111  1
2012 Wilson NS, Yang A, Yang B, Couto S, Stern H, Gogineni A, Pitti R, Marsters S, Weimer RM, Singh M, Ashkenazi A. Proapoptotic activation of death receptor 5 on tumor endothelial cells disrupts the vasculature and reduces tumor growth. Cancer Cell. 22: 80-90. PMID 22789540 DOI: 10.1016/J.Ccr.2012.05.014  1
2012 French DM, Lin BC, Wang M, Adams C, Shek T, Hötzel K, Bolon B, Ferrando R, Blackmore C, Schroeder K, Rodriguez LA, Hristopoulos M, Venook R, Ashkenazi A, Desnoyers LR. Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models. Plos One. 7: e36713. PMID 22615798 DOI: 10.1371/Journal.Pone.0036713  1
2012 Pham VC, Pitti R, Anania VG, Bakalarski CE, Bustos D, Jhunjhunwala S, Phung QT, Yu K, Forrest WF, Kirkpatrick DS, Ashkenazi A, Lill JR. Complementary proteomic tools for the dissection of apoptotic proteolysis events. Journal of Proteome Research. 11: 2947-54. PMID 22432722 DOI: 10.1021/Pr300035K  1
2012 Wilson NS, Yang B, Morelli AB, Koernig S, Yang A, Loeser S, Airey D, Provan L, Hass P, Braley H, Couto S, Drane D, Boyle J, Belz GT, Ashkenazi A, et al. ISCOMATRIX vaccines mediate CD8+ T-cell cross-priming by a MyD88-dependent signaling pathway. Immunology and Cell Biology. 90: 540-52. PMID 21894173 DOI: 10.1038/Icb.2011.71  1
2012 Kasubhai SM, Bendell JC, Kozloff M, Kapp AV, Ashkenazi A, Royer-Joo S, Portera CC. Phase Ib study of dulanermin combined with FOLFIRI (with or without bevacizumab [BV]) in previously treated patients (Pts) with metastatic colorectal cancer (mCRC). Journal of Clinical Oncology. 30: 3543-3543. DOI: 10.1200/Jco.2012.30.15_Suppl.3543  1
2011 Baron AD, O'Bryant CL, Choi Y, Royer-Joo S, Portera CC. Phase Ib study of drozitumab combined with cetuximab (CET) plus irinotecan (IRI) or with FOLFIRI with or without bevacizumab (BV) in previously treated patients (pts) with metastatic colorectal cancer (mCRC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 532. PMID 27985788 DOI: 10.1200/Jco.2011.29.4_Suppl.532  0.01
2011 Soria JC, Márk Z, Zatloukal P, Szima B, Albert I, Juhász E, Pujol JL, Kozielski J, Baker N, Smethurst D, Hei YJ, Ashkenazi A, Stern H, Amler L, Pan Y, et al. Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 4442-51. PMID 22010015 DOI: 10.1200/Jco.2011.37.2623  1
2011 Salvesen GS, Ashkenazi A. Snapshot: caspases. Cell. 147: 476-476.e1. PMID 22000022 DOI: 10.1016/j.cell.2011.09.030  1
2011 Almeida CR, Ashkenazi A, Shahaf G, Kaplan D, Davis DM, Mehr R. Human NK cells differ more in their KIR2DL1-dependent thresholds for HLA-Cw6-mediated inhibition than in their maximal killing capacity. Plos One. 6: e24927. PMID 21949790 DOI: 10.1371/journal.pone.0024927  1
2011 Chaudhuri A, Xie MH, Yang B, Mahapatra K, Liu J, Marsters S, Bodepudi S, Ashkenazi A. Distinct involvement of the Gab1 and Grb2 adaptor proteins in signal transduction by the related receptor tyrosine kinases RON and MET. The Journal of Biological Chemistry. 286: 32762-74. PMID 21784853 DOI: 10.1074/Jbc.M111.239384  1
2011 Ashkenazi A, Wexler-Cohen Y, Shai Y. Multifaceted action of Fuzeon as virus-cell membrane fusion inhibitor. Biochimica Et Biophysica Acta. 1808: 2352-8. PMID 21762676 DOI: 10.1016/J.Bbamem.2011.06.020  1
2011 Ikner A, Ashkenazi A. TWEAK induces apoptosis through a death-signaling complex comprising receptor-interacting protein 1 (RIP1), Fas-associated death domain (FADD), and caspase-8. The Journal of Biological Chemistry. 286: 21546-54. PMID 21525013 DOI: 10.1074/Jbc.M110.203745  0.01
2011 Biton S, Ashkenazi A. NEMO and RIP1 control cell fate in response to extensive DNA damage via TNF-α feedforward signaling. Cell. 145: 92-103. PMID 21458669 DOI: 10.1016/J.Cell.2011.02.023  0.01
2011 Ashkenazi A, Viard M, Wexler-Cohen Y, Blumenthal R, Shai Y. Viral envelope protein folding and membrane hemifusion are enhanced by the conserved loop region of HIV-1 gp41. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 25: 2156-66. PMID 21429941 DOI: 10.1096/Fj.10-175752  1
2011 Ashkenazi A, Schwedt T. Cluster headache--acute and prophylactic therapy. Headache. 51: 272-86. PMID 21284609 DOI: 10.1111/j.1526-4610.2010.01830.x  0.01
2011 Ashkenazi A, Shai Y. Insights into the mechanism of HIV-1 envelope induced membrane fusion as revealed by its inhibitory peptides. European Biophysics Journal : Ebj. 40: 349-57. PMID 21258789 DOI: 10.1007/S00249-010-0666-Z  1
2011 Wilson NS, Yang B, Yang A, Loeser S, Marsters S, Lawrence D, Li Y, Pitti R, Totpal K, Yee S, Ross S, Vernes JM, Lu Y, Adams C, Offringa R, ... ... Ashkenazi A, et al. An Fcγ receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells. Cancer Cell. 19: 101-13. PMID 21251615 DOI: 10.1016/J.Ccr.2010.11.012  1
2011 Pello SJ, Ashkenazi A. Spinal cord infarction in a woman with cardiac fibroelastoma. The Neurologist. 17: 47-8. PMID 21192195 DOI: 10.1097/NRL.0b013e3181d2a956  0.01
2011 Kozloff M, Messersmith WA, Kapp AV, Ashkenazi A, Royer-Joo S, Portera CC, Wainberg ZA. Phase Ib study of dulanermin combined with first-line FOLFOX plus bevacizumab (BV) in patients (Pts) with metastatic colorectal cancer (mCRC). Journal of Clinical Oncology. 29: 3552-3552. DOI: 10.1200/Jco.2012.30.15_Suppl.3552  1
2011 Du X, Li H, Ingalla E, Ross S, French D, Tien J, Ashkenazi A, Qing J. Abstract C63: Targeting FGFR3 with monoclonal antibody impairs bladder cancer growth in vivo. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-C63  1
2010 Bagri A, Ashkenazi A. UNCovering the molecular machinery of dependence receptor signaling. Molecular Cell. 40: 851-3. PMID 21172648 DOI: 10.1016/J.Molcel.2010.12.015  1
2010 Yang A, Wilson NS, Ashkenazi A. Proapoptotic DR4 and DR5 signaling in cancer cells: toward clinical translation. Current Opinion in Cell Biology. 22: 837-44. PMID 20813513 DOI: 10.1016/J.Ceb.2010.08.001  1
2010 Blumenfeld A, Ashkenazi A. Nerve blocks, trigger point injections and headache. Headache. 50: 953-4. PMID 20618813 DOI: 10.1111/j.1526-4610.2010.01685.x  1
2010 Blumenfeld A, Ashkenazi A, Grosberg B, Napchan U, Narouze S, Nett B, DePalma T, Rosenthal B, Tepper S, Lipton RB. Patterns of use of peripheral nerve blocks and trigger point injections among headache practitioners in the USA: Results of the American Headache Society Interventional Procedure Survey (AHS-IPS). Headache. 50: 937-42. PMID 20618812 DOI: 10.1111/j.1526-4610.2010.01676.x  1
2010 Wexler-Cohen Y, Ashkenazi A, Viard M, Blumenthal R, Shai Y. Virus-cell and cell-cell fusion mediated by the HIV-1 envelope glycoprotein is inhibited by short gp41 N-terminal membrane-anchored peptides lacking the critical pocket domain. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 24: 4196-202. PMID 20605950 DOI: 10.1096/Fj.09-151704  1
2010 Ashkenazi A, Yang I, Mushtaq A, Oshinsky ML. Is phonophobia associated with cutaneous allodynia in migraine? Journal of Neurology, Neurosurgery, and Psychiatry. 81: 1256-60. PMID 20562466 DOI: 10.1136/Jnnp.2009.198481  1
2010 Gonzalvez F, Ashkenazi A. New insights into apoptosis signaling by Apo2L/TRAIL. Oncogene. 29: 4752-65. PMID 20531300 DOI: 10.1038/Onc.2010.221  1
2010 Ashkenazi A, Blumenfeld A, Napchan U, Narouze S, Grosberg B, Nett R, DePalma T, Rosenthal B, Tepper S, Lipton RB. Peripheral nerve blocks and trigger point injections in headache management - a systematic review and suggestions for future research. Headache. 50: 943-52. PMID 20487039 DOI: 10.1111/j.1526-4610.2010.01675.x  1
2010 Herbst RS, Eckhardt SG, Kurzrock R, Ebbinghaus S, O'Dwyer PJ, Gordon MS, Novotny W, Goldwasser MA, Tohnya TM, Lum BL, Ashkenazi A, Jubb AM, Mendelson DS. Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 2839-46. PMID 20458040 DOI: 10.1200/Jco.2009.25.1991  1
2010 Ashkenazi A. Botulinum toxin type a for chronic migraine. Current Neurology and Neuroscience Reports. 10: 140-6. PMID 20425239 DOI: 10.1007/s11910-010-0087-5  0.01
2010 Ashkenazi A. Allodynia in cluster headache. Current Pain and Headache Reports. 14: 140-4. PMID 20425203 DOI: 10.1007/s11916-010-0097-7  0.01
2010 Stern HM, Padilla M, Wagner K, Amler L, Ashkenazi A. Development of immunohistochemistry assays to assess GALNT14 and FUT3/6 in clinical trials of dulanermin and drozitumab. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 1587-96. PMID 20179215 DOI: 10.1158/1078-0432.Ccr-09-3108  1
2010 Camidge DR, Herbst RS, Gordon MS, Eckhardt SG, Kurzrock R, Durbin B, Ing J, Tohnya TM, Sager J, Ashkenazi A, Bray G, Mendelson D. A phase I safety and pharmacokinetic study of the death receptor 5 agonistic antibody PRO95780 in patients with advanced malignancies. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 1256-63. PMID 20145186 DOI: 10.1158/1078-0432.Ccr-09-1267  1
2010 Zhou L, Hud-Shakoor Z, Hennessey C, Ashkenazi A. Upper cervical facet joint and spinal rami blocks for the treatment of cervicogenic headache. Headache. 50: 657-63. PMID 20132336 DOI: 10.1111/j.1526-4610.2010.01623.x  1
2010 Zangaladze A, Asadi-Pooya AA, Ashkenazi A, Sperling MR. Sporadic hemiplegic migraine and epilepsy associated with CACNA1A gene mutation. Epilepsy & Behavior : E&B. 17: 293-5. PMID 20071244 DOI: 10.1016/j.yebeh.2009.12.017  1
2010 Eimon PM, Ashkenazi A. The zebrafish as a model organism for the study of apoptosis. Apoptosis : An International Journal On Programmed Cell Death. 15: 331-49. PMID 20033783 DOI: 10.1007/S10495-009-0432-9  1
2009 Varfolomeev E, Alicke B, Elliott JM, Zobel K, West K, Wong H, Scheer JM, Ashkenazi A, Gould SE, Fairbrother WJ, Vucic D. X chromosome-linked inhibitor of apoptosis regulates cell death induction by proapoptotic receptor agonists. The Journal of Biological Chemistry. 284: 34553-60. PMID 19854829 DOI: 10.1074/Jbc.M109.040139  1
2009 Ashkenazi A, Mushtaq A, Yang I, Oshinsky ML. Ictal and interictal phonophobia in migraine-a quantitative controlled study. Cephalalgia : An International Journal of Headache. 29: 1042-8. PMID 19735532 DOI: 10.1111/J.1468-2982.2008.01834.X  1
2009 Ashkenazi A. The role of botulinum neurotoxin in pain management--an ongoing controversy. Current Pain and Headache Reports. 13: 249-52. PMID 19586585  0.01
2009 Abu-Rabeah K, Ashkenazi A, Atias D, Amir L, Marks RS. Highly sensitive amperometric immunosensor for the detection of Escherichia coli. Biosensors & Bioelectronics. 24: 3461-6. PMID 19501501 DOI: 10.1016/J.Bios.2009.04.042  1
2009 Jin Z, Li Y, Pitti R, Lawrence D, Pham VC, Lill JR, Ashkenazi A. Cullin3-based polyubiquitination and p62-dependent aggregation of caspase-8 mediate extrinsic apoptosis signaling. Cell. 137: 721-35. PMID 19427028 DOI: 10.1016/J.Cell.2009.03.015  1
2009 Marmura MJ, Abbas M, Ashkenazi A. Dynamic mechanical (brush) allodynia in cluster headache: a prevalence study in a tertiary headache clinic. The Journal of Headache and Pain. 10: 255-8. PMID 19421708 DOI: 10.1007/s10194-009-0124-4  0.01
2009 Qing J, Du X, Chen Y, Chan P, Li H, Wu P, Marsters S, Stawicki S, Tien J, Totpal K, Ross S, Stinson S, Dornan D, French D, Wang QR, ... ... Ashkenazi A, et al. Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice. The Journal of Clinical Investigation. 119: 1216-29. PMID 19381019 DOI: 10.1172/Jci38017  1
2009 Wilson NS, Dixit V, Ashkenazi A. Death receptor signal transducers: nodes of coordination in immune signaling networks. Nature Immunology. 10: 348-55. PMID 19295631 DOI: 10.1038/Ni.1714  1
2009 Ashkenazi A, Marks RS. Luminol-dependent chemiluminescence of human phagocyte cell lines: comparison between DMSO differentiated PLB 985 and HL 60 cells. Luminescence : the Journal of Biological and Chemical Luminescence. 24: 171-7. PMID 19291810 DOI: 10.1002/bio.1091  1
2009 Ashkenazi A, Silberstein S. Is botulinum toxin useful in treating headache? Yes. Current Treatment Options in Neurology. 11: 18-23. PMID 19094832  1
2009 Ashkenazi A, Abu-Rabeah K, Marks RS. Electrochemistry and chemiluminescence techniques compared in the detection of NADPH oxidase activity in phagocyte cells. Talanta. 77: 1460-5. PMID 19084665 DOI: 10.1016/j.talanta.2008.09.035  1
2008 Jin H, Yang R, Ross J, Fong S, Carano R, Totpal K, Lawrence D, Zheng Z, Koeppen H, Stern H, Schwall R, Ashkenazi A. Cooperation of the agonistic DR5 antibody apomab with chemotherapy to inhibit orthotopic lung tumor growth and improve survival. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 7733-40. PMID 19047100 DOI: 10.1158/1078-0432.Ccr-08-0670  1
2008 Ashkenazi A. Directing cancer cells to self-destruct with pro-apoptotic receptor agonists. Nature Reviews. Drug Discovery. 7: 1001-12. PMID 18989337 DOI: 10.1038/Nrd2637  0.01
2008 Ashkenazi A, Brown F. Images from headache: cluster-like headache associated with intra-cavernous carotid artery thrombosis. Headache. 48: 1214-5. PMID 18808501 DOI: 10.1111/j.1526-4610.2008.01225.x  0.01
2008 Shang Y, Mao Y, Batson J, Scales SJ, Phillips G, Lackner MR, Totpal K, Williams S, Yang J, Tang Z, Modrusan Z, Tan C, Liang WC, Tsai SP, Vanderbilt A, ... ... Ashkenazi A, et al. Antixenograft tumor activity of a humanized anti-insulin-like growth factor-I receptor monoclonal antibody is associated with decreased AKT activation and glucose uptake. Molecular Cancer Therapeutics. 7: 2599-608. PMID 18790743 DOI: 10.1158/1535-7163.Mct-07-2401  1
2008 Young WB, Marmura M, Ashkenazi A, Evans RW. Expert opinion: greater occipital nerve and other anesthetic injections for primary headache disorders. Headache. 48: 1122-5. PMID 18687084 DOI: 10.1111/j.1526-4610.2008.01192.x  1
2008 Ashkenazi A, Holland P, Eckhardt SG. Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 3621-30. PMID 18640940 DOI: 10.1200/Jco.2007.15.7198  0.01
2008 Ashkenazi A, Herbst RS. To kill a tumor cell: the potential of proapoptotic receptor agonists. The Journal of Clinical Investigation. 118: 1979-90. PMID 18523647 DOI: 10.1172/Jci34359  0.01
2008 Ashkenazi A. Targeting the extrinsic apoptosis pathway in cancer. Cytokine & Growth Factor Reviews. 19: 325-31. PMID 18495520 DOI: 10.1016/J.Cytogfr.2008.04.001  0.01
2008 Adams C, Totpal K, Lawrence D, Marsters S, Pitti R, Yee S, Ross S, Deforge L, Koeppen H, Sagolla M, Compaan D, Lowman H, Hymowitz S, Ashkenazi A. Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5. Cell Death and Differentiation. 15: 751-61. PMID 18219321 DOI: 10.1038/Sj.Cdd.4402306  1
2008 Ashkenazi A, Silberstein S. Botulinum toxin type A for the treatment of headache: why we say yes. Archives of Neurology. 65: 146-9. PMID 18195155 DOI: 10.1001/archneurol.2007.20  1
2008 Ashkenazi A, Matro R, Shaw JW, Abbas MA, Silberstein SD. Greater occipital nerve block using local anaesthetics alone or with triamcinolone for transformed migraine: a randomised comparative study. Journal of Neurology, Neurosurgery, and Psychiatry. 79: 415-7. PMID 17682008 DOI: 10.1136/jnnp.2007.124420  1
2008 Desnoyers LR, Pai R, Ferrando RE, Hötzel K, Le T, Ross J, Carano R, D'Souza A, Qing J, Mohtashemi I, Ashkenazi A, French DM. Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models. Oncogene. 27: 85-97. PMID 17599042 DOI: 10.1038/Sj.Onc.1210623  1
2008 Ashkenazi A, Wagner K, Punnnoose E, Lawrence D, Pitti R, Amler L. Identification of potentially predictive biomarkers for tumor sensitivity to proapoptotic receptor agonists Journal of Clinical Oncology. 26: 14505-14505. DOI: 10.1200/Jco.2008.26.15_Suppl.14505  1
2007 Xu L, Ashkenazi A, Chaudhuri A. Duffy antigen/receptor for chemokines (DARC) attenuates angiogenesis by causing senescence in endothelial cells. Angiogenesis. 10: 307-18. PMID 17955335 DOI: 10.1007/s10456-007-9084-y  1
2007 Wagner KW, Punnoose EA, Januario T, Lawrence DA, Pitti RM, Lancaster K, Lee D, von Goetz M, Yee SF, Totpal K, Huw L, Katta V, Cavet G, Hymowitz SG, Amler L, ... Ashkenazi A, et al. Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nature Medicine. 13: 1070-7. PMID 17767167 DOI: 10.1038/Nm1627  1
2007 Daniel D, Yang B, Lawrence DA, Totpal K, Balter I, Lee WP, Gogineni A, Cole MJ, Yee SF, Ross S, Ashkenazi A. Cooperation of the proapoptotic receptor agonist rhApo2L/TRAIL with the CD20 antibody rituximab against non-Hodgkin lymphoma xenografts. Blood. 110: 4037-46. PMID 17724141 DOI: 10.1182/Blood-2007-02-076075  1
2007 Ashkenazi A, Silberstein S. Menstrual migraine: a review of hormonal causes, prophylaxis and treatment. Expert Opinion On Pharmacotherapy. 8: 1605-13. PMID 17685879 DOI: 10.1517/14656566.8.11.1605  1
2007 Holst CR, Bou-Reslan H, Gore BB, Wong K, Grant D, Chalasani S, Carano RA, Frantz GD, Tessier-Lavigne M, Bolon B, French DM, Ashkenazi A. Secreted sulfatases Sulf1 and Sulf2 have overlapping yet essential roles in mouse neonatal survival. Plos One. 2: e575. PMID 17593974 DOI: 10.1371/Journal.Pone.0000575  1
2007 Ashkenazi A, Levin M. Greater occipital nerve block for migraine and other headaches: is it useful? Current Pain and Headache Reports. 11: 231-5. PMID 17504651  1
2007 Ashkenazi A, Silberstein S, Jakubowski M, Burstein R. Improved identification of allodynic migraine patients using a questionnaire. Cephalalgia : An International Journal of Headache. 27: 325-9. PMID 17376108 DOI: 10.1111/j.1468-2982.2007.01291.x  1
2007 Ashkenazi A, Abbas MA, Sharma DK, Silberstein SD. Hemicrania continua-like headache associated with internal carotid artery dissection may respond to indomethacin. Headache. 47: 127-30. PMID 17355508 DOI: 10.1111/j.1526-4610.2006.00637.x  1
2007 Ashkenazi A, Sholtzow M, Shaw JW, Burstein R, Young WB. Identifying cutaneous allodynia in chronic migraine using a practical clinical method. Cephalalgia : An International Journal of Headache. 27: 111-7. PMID 17257230 DOI: 10.1111/j.1468-2982.2006.01255.x  1
2007 Naumann U, Bähr O, Wolburg H, Altenberend S, Wick W, Liston P, Ashkenazi A, Weller M. Adenoviral expression of XIAP antisense RNA induces apoptosis in glioma cells and suppresses the growth of xenografts in nude mice. Gene Therapy. 14: 147-61. PMID 16957768 DOI: 10.1038/Sj.Gt.3302845  1
2007 Yee L, Fanale M, Dimick K, Calvert S, Robins C, Ing J, Novotny W, Ashkenazi A, Burris H. A phase IB safety and pharmacokinetic (PK) study of recombinant human Apo2L/TRAIL in combination with rituximab in patients with low-grade non-Hodgkin lymphoma Journal of Clinical Oncology. 25: 8078-8078. DOI: 10.1200/Jco.2007.25.18_Suppl.8078  0.01
2007 Naumann U, Bähr O, Wolburg H, Altenberend S, Wick W, Liston P, Ashkenazi A, Weller M. Adenoviral expression of XIAP antisense RNA induces apoptosis in glioma cells and suppresses the growth of xenografts in nude mice (Gene Therapy (2007) vol. 14 (147-161) 10.1038/sj.gt.3302845) Gene Therapy. 14: 1434-1437. DOI: 10.1038/Sj.Gt.3303002  1
2006 Ashkenazi A, Benlifer A, Korenblit J, Silberstein SD. Zonisamide for migraine prophylaxis in refractory patients. Cephalalgia : An International Journal of Headache. 26: 1199-202. PMID 16961786 DOI: 10.1111/j.1468-2982.2006.01191.x  1
2006 Eimon PM, Kratz E, Varfolomeev E, Hymowitz SG, Stern H, Zha J, Ashkenazi A. Delineation of the cell-extrinsic apoptosis pathway in the zebrafish. Cell Death and Differentiation. 13: 1619-30. PMID 16888647 DOI: 10.1038/Sj.Cdd.4402015  1
2006 Kratz E, Eimon PM, Mukhyala K, Stern H, Zha J, Strasser A, Hart R, Ashkenazi A. Functional characterization of the Bcl-2 gene family in the zebrafish. Cell Death and Differentiation. 13: 1631-40. PMID 16888646 DOI: 10.1038/Sj.Cdd.4402016  1
2006 Li B, Russell SJ, Compaan DM, Totpal K, Marsters SA, Ashkenazi A, Cochran AG, Hymowitz SG, Sidhu SS. Activation of the proapoptotic death receptor DR5 by oligomeric peptide and antibody agonists. Journal of Molecular Biology. 361: 522-36. PMID 16859704 DOI: 10.1016/J.Jmb.2006.06.042  1
2006 Austin CD, Lawrence DA, Peden AA, Varfolomeev EE, Totpal K, De Mazière AM, Klumperman J, Arnott D, Pham V, Scheller RH, Ashkenazi A. Death-receptor activation halts clathrin-dependent endocytosis. Proceedings of the National Academy of Sciences of the United States of America. 103: 10283-8. PMID 16801533 DOI: 10.1073/Pnas.0604044103  1
2006 LoPinto C, Young WB, Ashkenazi A. Comparison of dynamic (brush) and static (pressure) mechanical allodynia in migraine. Cephalalgia : An International Journal of Headache. 26: 852-6. PMID 16776701 DOI: 10.1111/j.1468-2982.2006.01121.x  1
2006 Ashkenazi A, Silberstein SD. Hormone-related headache: pathophysiology and treatment. Cns Drugs. 20: 125-41. PMID 16478288  1
2005 Hymowitz SG, Ashkenazi A. Toward small-molecule agonists of TNF receptors. Nature Chemical Biology. 1: 353-4. PMID 16370368 DOI: 10.1038/Nchembio1205-353  1
2005 Maecker H, Varfolomeev E, Kischkel F, Lawrence D, LeBlanc H, Lee W, Hurst S, Danilenko D, Li J, Filvaroff E, Yang B, Daniel D, Ashkenazi A. TWEAK attenuates the transition from innate to adaptive immunity. Cell. 123: 931-44. PMID 16325585 DOI: 10.1016/J.Cell.2005.09.022  1
2005 Jakubowski M, Silberstein S, Ashkenazi A, Burstein R. Can allodynic migraine patients be identified interictally using a questionnaire? Neurology. 65: 1419-22. PMID 16275830 DOI: 10.1212/01.wnl.0000183358.53939.38  1
2005 Varfolomeev E, Maecker H, Sharp D, Lawrence D, Renz M, Vucic D, Ashkenazi A. Molecular determinants of kinase pathway activation by Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand. The Journal of Biological Chemistry. 280: 40599-608. PMID 16227629 DOI: 10.1074/Jbc.M509560200  1
2005 Cretney E, McQualter JL, Kayagaki N, Yagita H, Bernard CC, Grewal IS, Ashkenazi A, Smyth MJ. TNF-related apoptosis-inducing ligand (TRAIL)/Apo2L suppresses experimental autoimmune encephalomyelitis in mice. Immunology and Cell Biology. 83: 511-9. PMID 16174101 DOI: 10.1111/J.1440-1711.2005.01358.X  1
2005 Ashkenazi A, Young WB. The effects of greater occipital nerve block and trigger point injection on brush allodynia and pain in migraine. Headache. 45: 350-4. PMID 15836572 DOI: 10.1111/j.1526-4610.2005.05073.x  1
2005 Sharp DA, Lawrence DA, Ashkenazi A. Selective knockdown of the long variant of cellular FLICE inhibitory protein augments death receptor-mediated caspase-8 activation and apoptosis. The Journal of Biological Chemistry. 280: 19401-9. PMID 15760909 DOI: 10.1074/Jbc.M413962200  1
2005 Davelaar EJ, Goshen-Gottstein Y, Ashkenazi A, Haarmann HJ, Usher M. The demise of short-term memory revisited: empirical and computational investigations of recency effects. Psychological Review. 112: 3-42. PMID 15631586 DOI: 10.1037/0033-295X.112.1.3  0.01
2005 Ashkenazi A, LoPinto C, Young WB. Referred cutaneous allodynia in a migraine patient without simultaneous headache. Cephalalgia : An International Journal of Headache. 25: 75-8. PMID 15606575 DOI: 10.1111/j.1468-2982.2004.00821.x  1
2005 Kelley RF, Totpal K, Lindstrom SH, Mathieu M, Billeci K, Deforge L, Pai R, Hymowitz SG, Ashkenazi A. Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling. The Journal of Biological Chemistry. 280: 2205-12. PMID 15520016 DOI: 10.1074/Jbc.M410660200  1
2004 Ravi R, Jain AJ, Schulick RD, Pham V, Prouser TS, Allen H, Mayer EG, Yu H, Pardoll DM, Ashkenazi A, Bedi A. Elimination of hepatic metastases of colon cancer cells via p53-independent cross-talk between irinotecan and Apo2 ligand/TRAIL. Cancer Research. 64: 9105-14. PMID 15604280 DOI: 10.1158/0008-5472.Can-04-2488  0.01
2004 Ashkenazi A, Young WB. Dynamic mechanical (brush) allodynia in cluster headache. Headache. 44: 1010-2. PMID 15546264 DOI: 10.1111/j.1526-4610.2004.04195.x  1
2004 Ashkenazi A, Silberstein SD. Periodic autonomic dysfunction without pain in a patient with cluster headache. Cephalalgia : An International Journal of Headache. 24: 1005-6. PMID 15482367 DOI: 10.1111/j.1468-2982.2004.00794.x  1
2004 Ashkenazi A, Levin M. Three common neuralgias. How to manage trigeminal, occipital, and postherpetic pain. Postgraduate Medicine. 116: 16-8, 21-4, 31-2 pas. PMID 15460087  1
2004 Young WB, Mateos V, Ashkenazi A. Occipital nerve block rapidly eliminates allodynia far from the site of headache: a case report. Cephalalgia : An International Journal of Headache. 24: 906-7. PMID 15377325 DOI: 10.1111/j.1468-2982.2004.00779.x  1
2004 Ashkenazi A, Silberstein SD. Headache management for the pain specialist. Regional Anesthesia and Pain Medicine. 29: 462-75. PMID 15372392  1
2004 Ashkenazi A, Marks LE. Effect of endogenous attention on detection of weak gustatory and olfactory flavors. Perception & Psychophysics. 66: 596-608. PMID 15311659 DOI: 10.3758/Bf03194904  1
2004 Jin H, Yang R, Fong S, Totpal K, Lawrence D, Zheng Z, Ross J, Koeppen H, Schwall R, Ashkenazi A. Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand cooperates with chemotherapy to inhibit orthotopic lung tumor growth and improve survival. Cancer Research. 64: 4900-5. PMID 15256461 DOI: 10.1158/0008-5472.Can-04-0408  1
2004 Kelley SK, Ashkenazi A. Targeting death receptors in cancer with Apo2L/TRAIL. Current Opinion in Pharmacology. 4: 333-9. PMID 15251125 DOI: 10.1016/J.Coph.2004.02.006  0.01
2004 Ashkenazi A, Fritz M, Buckley J, Marks LE. The Temporal Automated System for Taste Experiments (TASTE). Behavior Research Methods, Instruments, & Computers : a Journal of the Psychonomic Society, Inc. 36: 83-8. PMID 15190702 DOI: 10.3758/Bf03195552  1
2004 Varfolomeev EE, Ashkenazi A. Tumor necrosis factor: an apoptosis JuNKie? Cell. 116: 491-7. PMID 14980217 DOI: 10.1016/S0092-8674(04)00166-7  0.01
2004 Ashkenazi A, Silberstein SD. Botulinum toxin and other new approaches to migraine therapy. Annual Review of Medicine. 55: 505-18. PMID 14746533 DOI: 10.1146/annurev.med.55.091902.104440  1
2004 Varfolomeev E, Kischkel F, Martin F, Seshasayee D, Wang H, Lawrence D, Olsson C, Tom L, Erickson S, French D, Schow P, Grewal IS, Ashkenazi A. APRIL-deficient mice have normal immune system development. Molecular and Cellular Biology. 24: 997-1006. PMID 14729948 DOI: 10.1128/Mcb.24.3.997-1006.2004  1
2003 Ashkenazi A, Silberstein SD. The evolving management of migraine. Current Opinion in Neurology. 16: 341-5. PMID 12858071 DOI: 10.1097/01.wco.0000073935.19076.47  1
2003 Almasan A, Ashkenazi A. Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. Cytokine & Growth Factor Reviews. 14: 337-48. PMID 12787570 DOI: 10.1016/S1359-6101(03)00029-7  0.01
2003 Miller K, Meng G, Liu J, Hurst A, Hsei V, Wong WL, Ekert R, Lawrence D, Sherwood S, DeForge L, Gaudreault J, Keller G, Sliwkowski M, Ashkenazi A, Presta L. Design, construction, and in vitro analyses of multivalent antibodies. Journal of Immunology (Baltimore, Md. : 1950). 170: 4854-61. PMID 12728922 DOI: 10.4049/Jimmunol.170.9.4854  1
2003 LeBlanc HN, Ashkenazi A. Apo2L/TRAIL and its death and decoy receptors. Cell Death and Differentiation. 10: 66-75. PMID 12655296 DOI: 10.1038/Sj.Cdd.4401187  0.01
2002 Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nature Reviews. Cancer. 2: 420-30. PMID 12189384 DOI: 10.1038/Nrc821  0.01
2002 Poulaki V, Mitsiades CS, Kotoula V, Tseleni-Balafouta S, Ashkenazi A, Koutras DA, Mitsiades N. Regulation of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in thyroid carcinoma cells. The American Journal of Pathology. 161: 643-54. PMID 12163389 DOI: 10.1016/S0002-9440(10)64220-4  0.01
2002 LeBlanc H, Lawrence D, Varfolomeev E, Totpal K, Morlan J, Schow P, Fong S, Schwall R, Sinicropi D, Ashkenazi A. Tumor-cell resistance to death receptor--induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. Nature Medicine. 8: 274-81. PMID 11875499 DOI: 10.1038/Nm0302-274  1
2001 Kischkel FC, Lawrence DA, Tinel A, LeBlanc H, Virmani A, Schow P, Gazdar A, Blenis J, Arnott D, Ashkenazi A. Death receptor recruitment of endogenous caspase-10 and apoptosis initiation in the absence of caspase-8. The Journal of Biological Chemistry. 276: 46639-46. PMID 11583996 DOI: 10.1074/Jbc.M105102200  1
2001 Wang H, Marsters SA, Baker T, Chan B, Lee WP, Fu L, Tumas D, Yan M, Dixit VM, Ashkenazi A, Grewal IS. TACI-ligand interactions are required for T cell activation and collagen-induced arthritis in mice. Nature Immunology. 2: 632-7. PMID 11429548 DOI: 10.1038/89782  1
2001 Pollack IF, Erff M, Ashkenazi A. Direct stimulation of apoptotic signaling by soluble Apo2l/tumor necrosis factor-related apoptosis-inducing ligand leads to selective killing of glioma cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 7: 1362-9. PMID 11350907  0.01
2001 Chuntharapai A, Dodge K, Grimmer K, Schroeder K, Marsters SA, Koeppen H, Ashkenazi A, Kim KJ. Isotype-dependent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4. Journal of Immunology (Baltimore, Md. : 1950). 166: 4891-8. PMID 11290766 DOI: 10.4049/Jimmunol.166.8.4891  1
2001 Roth W, Isenmann S, Nakamura M, Platten M, Wick W, Kleihues P, Bähr M, Ohgaki H, Ashkenazi A, Weller M. Soluble decoy receptor 3 is expressed by malignant gliomas and suppresses CD95 ligand-induced apoptosis and chemotaxis. Cancer Research. 61: 2759-65. PMID 11289159  1
2001 Lawrence D, Shahrokh Z, Marsters S, Achilles K, Shih D, Mounho B, Hillan K, Totpal K, DeForge L, Schow P, Hooley J, Sherwood S, Pai R, Leung S, Khan L, ... ... Ashkenazi A, et al. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nature Medicine. 7: 383-5. PMID 11283636 DOI: 10.1038/86397  1
2000 Kischkel FC, Ashkenazi A. Combining enhanced metabolic labeling with immunoblotting to detect interactions of endogenous cellular proteins. Biotechniques. 29: 506-10, 512. PMID 10997264 DOI: 10.2144/00293St02  1
2000 Ashkenazi A, Grewal IS, Dixit VM. Response to 'Secreted IgM versus BLyS in germinal center formation' Nature Immunology. 1: 179. PMID 10973268 DOI: 10.1038/79710  1
2000 Marsters SA, Yan M, Pitti RM, Haas PE, Dixit VM, Ashkenazi A. Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI. Current Biology : Cb. 10: 785-8. PMID 10898980 DOI: 10.1016/S0960-9822(00)00566-2  1
2000 Kischkel FC, Lawrence DA, Chuntharapai A, Schow P, Kim KJ, Ashkenazi A. Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity. 12: 611-20. PMID 10894161 DOI: 10.1016/S1074-7613(00)80212-5  1
2000 Yan M, Marsters SA, Grewal IS, Wang H, Ashkenazi A, Dixit VM. Identification of a receptor for BLyS demonstrates a crucial role in humoral immunity. Nature Immunology. 1: 37-41. PMID 10881172 DOI: 10.1038/76889  1
2000 Zhou Q, Fukushima P, DeGraff W, Mitchell JB, Stetler Stevenson M, Ashkenazi A, Steeg PS. Radiation and the Apo2L/TRAIL apoptotic pathway preferentially inhibit the colonization of premalignant human breast cells overexpressing cyclin D1. Cancer Research. 60: 2611-5. PMID 10825131  0.01
2000 Cohen HA, Ashkenazi A, Barzilai A, Lahat E. Nocturnal acute laryngospasm in children: a possible epileptic phenomenon. Journal of Child Neurology. 15: 202-4. PMID 10757476  1
2000 Halaas O, Vik R, Ashkenazi A, Espevik T. Lipopolysaccharide induces expression of APO2 ligand/TRAIL in human monocytes and macrophages. Scandinavian Journal of Immunology. 51: 244-50. PMID 10736093  1
2000 Ashkenazi A, Kaufman Y, Ben-Hur T. Bilateral focal motor status epilepticus with retained consciousness after stroke. Neurology. 54: 976-8. PMID 10690997  0.01
2000 Hymowitz SG, O'Connell MP, Ultsch MH, Hurst A, Totpal K, Ashkenazi A, de Vos AM, Kelley RF. A unique zinc-binding site revealed by a high-resolution X-ray structure of homotrimeric Apo2L/TRAIL. Biochemistry. 39: 633-40. PMID 10651627 DOI: 10.1021/Bi992242L  1
1999 Ashkenazi A, Ovadia H, Abramsky O. [Paraneoplastic autoimmune syndromes of the nervous system]. Harefuah. 137: 394-9. PMID 11419044  1
1999 Roth W, Isenmann S, Naumann U, Kügler S, Bähr M, Dichgans J, Ashkenazi A, Weller M. Locoregional Apo2L/TRAIL eradicates intracranial human malignant glioma xenografts in athymic mice in the absence of neurotoxicity. Biochemical and Biophysical Research Communications. 265: 479-83. PMID 10558893 DOI: 10.1006/Bbrc.1999.1693  1
1999 Hymowitz SG, Christinger HW, Fuh G, Ultsch M, O'Connell M, Kelley RF, Ashkenazi A, de Vos AM. Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5. Molecular Cell. 4: 563-71. PMID 10549288 DOI: 10.1016/S1097-2765(00)80207-5  1
1999 Marsters SA, Pitti RA, Sheridan JP, Ashkenazi A. Control of apoptosis signaling by Apo2 ligand. Recent Progress in Hormone Research. 54: 225-34. PMID 10548878  1
1999 Johnsen AC, Haux J, Steinkjer B, Nonstad U, Egeberg K, Sundan A, Ashkenazi A, Espevik T. Regulation of APO-2 ligand/trail expression in NK cells-involvement in NK cell-mediated cytotoxicity. Cytokine. 11: 664-72. PMID 10479402 DOI: 10.1006/Cyto.1999.0489  1
1999 Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert A, DeForge L, Koumenis IL, Lewis D, Harris L, Bussiere J, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. The Journal of Clinical Investigation. 104: 155-62. PMID 10411544 DOI: 10.1172/Jci6926  1
1999 Ashkenazi A, Freeman S, Argov Z. Effects of cholinergic blockers on auditory brain-stem evoked potentials in rats. Journal of the Neurological Sciences. 164: 124-8. PMID 10402022  1
1999 Chuntharapai A, Gibbs V, Lu J, Ow A, Marsters S, Ashkenazi A, De Vos A, Jin Kim K. Determination of residues involved in ligand binding and signal transmission in the human IFN-alpha receptor 2. Journal of Immunology (Baltimore, Md. : 1950). 163: 766-73. PMID 10395669  1
1999 Mori S, Murakami-Mori K, Nakamura S, Ashkenazi A, Bonavida B. Sensitization of AIDS-Kaposi's sarcoma cells to Apo-2 ligand-induced apoptosis by actinomycin D. Journal of Immunology (Baltimore, Md. : 1950). 162: 5616-23. PMID 10228045  0.01
1999 Ashkenazi A, Dixit VM. Apoptosis control by death and decoy receptors. Current Opinion in Cell Biology. 11: 255-60. PMID 10209153 DOI: 10.1016/S0955-0674(99)80034-9  1
1999 Gurney AL, Marsters SA, Huang RM, Pitti RM, Mark DT, Baldwin DT, Gray AM, Dowd AD, Brush AD, Heldens AD, Schow AD, Goddard AD, Wood WI, Baker KP, Godowski PJ, ... Ashkenazi A, et al. Identification of a new member of the tumor necrosis factor family and its receptor, a human ortholog of mouse GITR. Current Biology : Cb. 9: 215-8. PMID 10074428 DOI: 10.1016/S0960-9822(99)80093-1  1
1998 Pitti RM, Marsters SA, Lawrence DA, Roy M, Kischkel FC, Dowd P, Huang A, Donahue CJ, Sherwood SW, Baldwin DT, Godowski PJ, Wood WI, Gurney AL, Hillan KJ, Cohen RL, ... ... Ashkenazi A, et al. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature. 396: 699-703. PMID 9872321 DOI: 10.1038/25387  1
1998 Dror Y, Blachar Y, Cohen P, Livni N, Rosenmann E, Ashkenazi A. Systemic lupus erythematosus associated with acute Epstein-Barr virus infection. American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation. 32: 825-8. PMID 9820454  1
1998 Karussis D, Leker RR, Ashkenazi A, Abramsky O. A subgroup of multiple sclerosis patients with anticardiolipin antibodies and unusual clinical manifestations: do they represent a new nosological entity? Annals of Neurology. 44: 629-34. PMID 9778261 DOI: 10.1002/ana.410440408  1
1998 Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science (New York, N.Y.). 281: 1305-8. PMID 9721089 DOI: 10.1126/Science.281.5381.1305  1
1998 Rieger J, Naumann U, Glaser T, Ashkenazi A, Weller M. APO2 ligand: a novel lethal weapon against malignant glioma? Febs Letters. 427: 124-8. PMID 9613612 DOI: 10.1016/S0014-5793(98)00409-8  1
1998 Marsters SA, Sheridan JP, Pitti RM, Brush J, Goddard A, Ashkenazi A. Identification of a ligand for the death-domain-containing receptor Apo3. Current Biology : Cb. 8: 525-8. PMID 9560343 DOI: 10.1016/S0960-9822(98)70204-0  1
1998 Pender SL, Fell JM, Chamow SM, Ashkenazi A, MacDonald TT. A p55 TNF receptor immunoadhesin prevents T cell-mediated intestinal injury by inhibiting matrix metalloproteinase production. Journal of Immunology (Baltimore, Md. : 1950). 160: 4098-103. PMID 9558121  1
1998 Cohen O, Steiner I, Argov Z, Ashkenazi A, Diment J, Saada A, River Y. Mitochondrial myopathy with atypical subacute presentation. Journal of Neurology, Neurosurgery, and Psychiatry. 64: 410-1. PMID 9527168  1
1997 Marsters SA, Sheridan JP, Pitti RM, Huang A, Skubatch M, Baldwin D, Yuan J, Gurney A, Goddard AD, Godowski P, Ashkenazi A. A novel receptor for Apo2L/TRAIL contains a truncated death domain. Current Biology : Cb. 7: 1003-6. PMID 9382840 DOI: 10.1016/S0960-9822(06)00422-2  1
1997 Sever Y, Ashkenazi A, Tyano S, Weizman A. Iron treatment in children with attention deficit hyperactivity disorder. A preliminary report. Neuropsychobiology. 35: 178-80. PMID 9246217  0.01
1997 Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, Ramakrishnan L, Gray CL, Baker K, Wood WI, Goddard AD, Godowski P, Ashkenazi A. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science (New York, N.Y.). 277: 818-21. PMID 9242611 DOI: 10.1126/Science.277.5327.818  1
1997 Marsters SA, Ayres TM, Skubatch M, Gray CL, Rothe M, Ashkenazi A. Herpesvirus entry mediator, a member of the tumor necrosis factor receptor (TNFR) family, interacts with members of the TNFR-associated factor family and activates the transcription factors NF-kappaB and AP-1. The Journal of Biological Chemistry. 272: 14029-32. PMID 9162022 DOI: 10.1074/jbc.272.22.14029  1
1997 Ashkenazi A, Chamow SM. Immunoadhesins as research tools and therapeutic agents. Current Opinion in Immunology. 9: 195-200. PMID 9099788 DOI: 10.1016/S0952-7915(97)80135-5  1
1996 Marsters SA, Sheridan JP, Donahue CJ, Pitti RM, Gray CL, Goddard AD, Bauer KD, Ashkenazi A. Apo-3, a new member of the tumor necrosis factor receptor family, contains a death domain and activates apoptosis and NF-kappa B. Current Biology : Cb. 6: 1669-76. PMID 8994832 DOI: 10.1016/S0960-9822(02)70791-4  1
1996 Marsters SA, Pitti RM, Donahue CJ, Ruppert S, Bauer KD, Ashkenazi A. Activation of apoptosis by Apo-2 ligand is independent of FADD but blocked by CrmA. Current Biology : Cb. 6: 750-2. PMID 8793301 DOI: 10.1016/S0960-9822(09)00456-4  1
1996 Chamow SM, Ashkenazi A. Immunoadhesins: principles and applications. Trends in Biotechnology. 14: 52-60. PMID 8746117 DOI: 10.1016/0167-7799(96)80921-8  1
1996 Van Zee KJ, Moldawer LL, Oldenburg HS, Thompson WA, Stackpole SA, Montegut WJ, Rogy MA, Meschter C, Gallati H, Schiller CD, Richter WF, Loetscher H, Ashkenazi A, Chamow SM, Wurm F, et al. Protection against lethal Escherichia coli bacteremia in baboons (Papio anubis) by pretreatment with a 55-kDa TNF receptor (CD120a)-Ig fusion protein, Ro 45-2081. Journal of Immunology (Baltimore, Md. : 1950). 156: 2221-30. PMID 8690912  1
1996 Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. The Journal of Biological Chemistry. 271: 12687-90. PMID 8663110 DOI: 10.1074/Jbc.271.22.12687  1
1996 Bach EA, Tanner JW, Marsters S, Ashkenazi A, Aguet M, Shaw AS, Schreiber RD. Ligand-induced assembly and activation of the gamma interferon receptor in intact cells. Molecular and Cellular Biology. 16: 3214-21. PMID 8649432 DOI: 10.1128/Mcb.16.6.3214  1
1995 Chamow SM, Zhang D, Tan XY, Mhatre SM, Marsters SA, Peers DH, Byrn RA, Ashkenazi A, Junghans RP. A humanized, bispecific immunoadhesin-antibody that retargets CD3+ effectors to kill HIV-1-infected cells. Journal of Hematotherapy. 4: 439-46. PMID 8581382 DOI: 10.1089/Scd.1.1995.4.439  1
1995 Oksenberg D, Havlik S, Peroutka SJ, Ashkenazi A. The third intracellular loop of the 5-hydroxytryptamine2A receptor determines effector coupling specificity. Journal of Neurochemistry. 64: 1440-7. PMID 7891070 DOI: 10.1046/J.1471-4159.1995.64041440.X  1
1995 Marsters SA, Pennica D, Bach E, Schreiber RD, Ashkenazi A. Interferon gamma signals via a high-affinity multisubunit receptor complex that contains two types of polypeptide chain. Proceedings of the National Academy of Sciences of the United States of America. 92: 5401-5. PMID 7777519 DOI: 10.1073/Pnas.92.12.5401  1
1995 Jin H, Yang R, Marsters S, Ashkenazi A, Bunting S, Marra MN, Scott RW, Baker JB. Protection against endotoxic shock by bactericidal/permeability-increasing protein in rats. The Journal of Clinical Investigation. 95: 1947-52. PMID 7706502 DOI: 10.1172/Jci117877  1
1995 Bach EA, Szabo SJ, Dighe AS, Ashkenazi A, Aguet M, Murphy KM, Schreiber RD. Ligand-induced autoregulation of IFN-gamma receptor beta chain expression in T helper cell subsets. Science (New York, N.Y.). 270: 1215-8. PMID 7502050 DOI: 10.1126/Science.270.5239.1215  1
1995 Ashkenazi A, Chamow SM. Immunoadhesins: An Alternative to Human Monoclonal Antibodies Methods. 8: 104-115. DOI: 10.1006/Meth.1995.9996  1
1994 Haak-Frendscho M, Marsters SA, Mordenti J, Brady S, Gillett NA, Chen SA, Ashkenazi A. Inhibition of TNF by a TNF receptor immunoadhesin. Comparison to an anti-TNF monoclonal antibody. Journal of Immunology (Baltimore, Md. : 1950). 152: 1347-53. PMID 8301136  1
1994 Tighe MR, Hall MA, Cardi E, Ashkenazi A, Lanchbury JS, Ciclitira PJ. Associations between alleles of the major histocompatibility complex-encoded ABC transporter gene TAP2, HLA class II alleles, and celiac disease susceptibility. Human Immunology. 39: 9-16. PMID 8181966  1
1994 Means RT, Krantz SB, Luna J, Marsters SA, Ashkenazi A. Inhibition of murine erythroid colony formation in vitro by interferon gamma and correction by interferon receptor immunoadhesin. Blood. 83: 911-5. PMID 8111063  1
1994 Flasher D, Konopka K, Chamow SM, Dazin P, Ashkenazi A, Pretzer E, Düzgünes N. Liposome targeting to human immunodeficiency virus type 1-infected cells via recombinant soluble CD4 and CD4 immunoadhesin (CD4-IgG). Biochimica Et Biophysica Acta. 1194: 185-96. PMID 8075135 DOI: 10.1016/0005-2736(94)90219-4  1
1994 Chamow SM, Kogan TP, Venuti M, Gadek T, Harris RJ, Peers DH, Mordenti J, Shak S, Ashkenazi A. Modification of CD4 immunoadhesin with monomethoxypoly(ethylene glycol) aldehyde via reductive alkylation. Bioconjugate Chemistry. 5: 133-40. PMID 8031876 DOI: 10.1021/Bc00026A005  1
1994 Pitti RM, Marsters SA, Haak-Frendscho M, Osaka GC, Mordenti J, Chamow SM, Ashkenazi A. Molecular and biological properties of an interleukin-1 receptor immunoadhesin. Molecular Immunology. 31: 1345-51. PMID 7997246 DOI: 10.1016/0161-5890(94)90053-1  1
1994 Beck JT, Marsters SA, Harris RJ, Carter P, Ashkenazi A, Chamow SM. Generation of soluble interleukin-1 receptor from an immunoadhesin by specific cleavage. Molecular Immunology. 31: 1335-44. PMID 7997245 DOI: 10.1016/0161-5890(94)90052-3  1
1994 Vaisman N, Zadik Z, Akivias A, Voet H, Katz I, Yair S, Ashkenazi A. Changes in body composition, resting energy expenditure, and thermic effect of food in short children on growth hormone therapy. Metabolism: Clinical and Experimental. 43: 1543-8. PMID 7990709 DOI: 10.1016/0026-0495(94)90014-0  1
1994 Jin H, Yang R, Marsters SA, Bunting SA, Wurm FM, Chamow SM, Ashkenazi A. Protection against rat endotoxic shock by p55 tumor necrosis factor (TNF) receptor immunoadhesin: comparison with anti-TNF monoclonal antibody. The Journal of Infectious Diseases. 170: 1323-6. PMID 7963738 DOI: 10.1093/Infdis/170.5.1323  1
1994 Chamow SM, Zhang DZ, Tan XY, Mhatre SM, Marsters SA, Peers DH, Byrn RA, Ashkenazi A, Junghans RP. A humanized, bispecific immunoadhesin-antibody that retargets CD3+ effectors to kill HIV-1-infected cells. Journal of Immunology (Baltimore, Md. : 1950). 153: 4268-80. PMID 7930627  1
1994 Grinbaum A, Ashkenazi A, Avni I, Treister G. Ocular inflammation as an initial manifestation of cutaneous polyarteritis nodosa. The British Journal of Dermatology. 131: 451-2. PMID 7918025  0.01
1993 Dror Y, Ashkenazi A. [Risk of HIV infection among health care workers]. Harefuah. 124: 151-4. PMID 8495884  1
1993 Ashkenazi A. The LIF test. Acta Paediatrica (Oslo, Norway : 1992). 82: 260. PMID 8495080  0.01
1993 Frydman M, Cohen HA, Ashkenazi A, Varsano I. Familial segregation of cervical ribs, Sprengel anomaly, preaxial polydactyly, anal atresia, and urethral obstruction: a new syndrome? American Journal of Medical Genetics. 45: 717-20. PMID 8456850 DOI: 10.1002/ajmg.1320450611  1
1993 Haak-Frendscho M, Marsters SA, Chamow SM, Peers DH, Simpson NJ, Ashkenazi A. Inhibition of interferon-gamma by an interferon-gamma receptor immunoadhesin. Immunology. 79: 594-9. PMID 8406584  1
1993 Pennica D, Lam VT, Weber RF, Kohr WJ, Basa LJ, Spellman MW, Ashkenazi A, Shire SJ, Goeddel DV. Biochemical characterization of the extracellular domain of the 75-kilodalton tumor necrosis factor receptor. Biochemistry. 32: 3131-8. PMID 8384489 DOI: 10.1021/Bi00063A027  1
1993 Cohen HA, Nussinovitch M, Ashkenazi A, Straussberg R, Kaushansky A. Benign abducens nerve palsy of childhood. Pediatric Neurology. 9: 394-5. PMID 8292216  1
1993 Barfod ET, Zheng Y, Kuang WJ, Hart MJ, Evans T, Cerione RA, Ashkenazi A. Cloning and expression of a human CDC42 GTPase-activating protein reveals a functional SH3-binding domain. The Journal of Biological Chemistry. 268: 26059-62. PMID 8253717  1
1993 Vandenplas Y, Ashkenazi A, Belli D, Boige N, Bouquet J, Cadranel S, Cezard JP, Cucchiara S, Dupont C, Geboes K. A proposition for the diagnosis and treatment of gastro-oesophageal reflux disease in children: a report from a working group on gastro-oesophageal reflux disease. Working Group of the European Society of Paediatric Gastro-enterology and Nutrition (ESPGAN). European Journal of Pediatrics. 152: 704-11. PMID 8223796  0.01
1993 Tighe MR, Hall MA, Ashkenazi A, Siegler E, Lanchbury JS, Ciclitira PJ. Celiac disease among Ashkenazi Jews from Israel. A study of the HLA class II alleles and their associations with disease susceptibility. Human Immunology. 38: 270-6. PMID 8138422  1
1993 Ashkenazi A, Capon DJ, Ward RH. Immunoadhesins. International Reviews of Immunology. 10: 219-27. PMID 7689624  1
1992 Moore JP, McKeating JA, Huang YX, Ashkenazi A, Ho DD. Virions of primary human immunodeficiency virus type 1 isolates resistant to soluble CD4 (sCD4) neutralization differ in sCD4 binding and glycoprotein gp120 retention from sCD4-sensitive isolates. Journal of Virology. 66: 235-43. PMID 1727487 DOI: 10.1128/jvi.66.1.235-243.1992  1
1992 Chamow SM, Kogan TP, Peers DH, Hastings RC, Byrn RA, Ashkenazi A. Conjugation of soluble CD4 without loss of biological activity via a novel carbohydrate-directed cross-linking reagent. The Journal of Biological Chemistry. 267: 15916-22. PMID 1639820  1
1992 Cohen HA, Ashkenazi A, Nussinovitch M, Amir J, Hart J, Frydman M. Mumps-associated acute cerebellar ataxia. American Journal of Diseases of Children (1960). 146: 930-1. PMID 1636659  1
1992 Cohen HA, Ashkenazi A, Nussinovitch M, Gross S, Frydman M. Fixed drug eruption of the scrotum due to methylphenidate. The Annals of Pharmacotherapy. 26: 1378-9. PMID 1477441  1
1992 Oksenberg D, Marsters SA, O'Dowd BF, Jin H, Havlik S, Peroutka SJ, Ashkenazi A. A single amino-acid difference confers major pharmacological variation between human and rodent 5-HT1B receptors. Nature. 360: 161-3. PMID 1436092 DOI: 10.1038/360161A0  1
1992 Chamow SM, Duliege AM, Ammann A, Kahn JO, Allen JD, Eichberg JW, Byrn RA, Capon DJ, Ward RH, Ashkenazi A. CD4 immunoadhesins in anti-HIV therapy: new developments. International Journal of Cancer. Supplement = Journal International Du Cancer. Supplement. 7: 69-72. PMID 1428410  1
1992 Ashkenazi A, Cooper M, Chemke J, Simon D, Cohen C, Mass N, Schattner A. The quality assurance committee in a general hospital: its use in improvement of the medical record. Israel Journal of Medical Sciences. 28: 714-7. PMID 1399501  1
1992 Jin H, Oksenberg D, Ashkenazi A, Peroutka SJ, Duncan AM, Rozmahel R, Yang Y, Mengod G, Palacios JM, O'Dowd BF. Characterization of the human 5-hydroxytryptamine1B receptor. The Journal of Biological Chemistry. 267: 5735-8. PMID 1348246  1
1992 Marsters SA, Frutkin AD, Simpson NJ, Fendly BM, Ashkenazi A. Identification of cysteine-rich domains of the type 1 tumor necrosis factor receptor involved in ligand binding. The Journal of Biological Chemistry. 267: 5747-50. PMID 1313418  1
1991 Ashkenazi A, Smith DH, Marsters SA, Riddle L, Gregory TJ, Ho DD, Capon DJ. Resistance of primary isolates of human immunodeficiency virus type 1 to soluble CD4 is independent of CD4-rgp120 binding affinity. Proceedings of the National Academy of Sciences of the United States of America. 88: 7056-60. PMID 1871120 DOI: 10.1073/Pnas.88.16.7056  1
1991 Ashkenazi A, Marsters SA, Capon DJ, Chamow SM, Figari IS, Pennica D, Goeddel DV, Palladino MA, Smith DH. Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin. Proceedings of the National Academy of Sciences of the United States of America. 88: 10535-9. PMID 1660140 DOI: 10.1073/Pnas.88.23.10535  1
1990 Ashkenazi A, Presta LG, Marsters SA, Camerato TR, Rosenthal KA, Fendly BM, Capon DJ. Mapping the CD4 binding site for human immunodeficiency virus by alanine-scanning mutagenesis. Proceedings of the National Academy of Sciences of the United States of America. 87: 7150-4. PMID 2402498 DOI: 10.1073/Pnas.87.18.7150  1
1990 Ashkenazi A. [Celiac disease where to? An update]. Harefuah. 118: 167-72. PMID 2187772  0.01
1990 Chamow SM, Peers DH, Byrn RA, Mulkerrin MG, Harris RJ, Wang WC, Bjorkman PJ, Capon DJ, Ashkenazi A. Enzymatic cleavage of a CD4 immunoadhesin generates crystallizable, biologically active Fd-like fragments. Biochemistry. 29: 9885-91. PMID 2125484 DOI: 10.1021/Bi00494A019  1
1989 Elberg G, Ashkenazi A, Gertler A. Solubilization and characterization of lactogenic hormone receptor from kidney of lactating cow. Molecular and Cellular Endocrinology. 61: 77-85. PMID 2744217 DOI: 10.1016/0303-7207(89)90191-3  0.01
1989 Ashkenazi A, Ramachandran J, Capon DJ. Acetylcholine analogue stimulates DNA synthesis in brain-derived cells via specific muscarinic receptor subtypes. Nature. 340: 146-50. PMID 2739737 DOI: 10.1038/340146A0  1
1989 Ramachandran J, Peralta EG, Ashkenazi A, Winslow JW, Smith DH, Capon DJ. Structural and functional diversity of muscarinic acetylcholine receptor subtypes. Progress in Clinical and Biological Research. 289: 327-39. PMID 2726804  1
1989 Ashkenazi A, Peralta EG, Winslow JW, Ramachandran J, Capon DJ. Functional diversity of muscarinic receptor subtypes in cellular signal transduction and growth. Trends in Pharmacological Sciences. 16-22. PMID 2694517  1
1989 Ramachandran J, Peralta EG, Ashkenazi A, Winslow JW, Capon DJ. The structural and functional interrelationships of muscarinic acetylcholine receptor subtypes. Bioessays : News and Reviews in Molecular, Cellular and Developmental Biology. 10: 54-7. PMID 2655586 DOI: 10.1002/Bies.950100205  1
1989 Lamarre D, Ashkenazi A, Fleury S, Smith DH, Sekaly RP, Capon DJ. The MHC-binding and gp120-binding functions of CD4 are separable. Science (New York, N.Y.). 245: 743-6. PMID 2549633 DOI: 10.1126/Science.2549633  1
1989 Sarel R, Miskin A, Ashkenazi A. [Penicillin VK absorption during fasting and after eating]. Harefuah. 117: 430-2. PMID 2516005  1
1989 Ashkenazi A, Peralta EG, Winslow JW, Ramachandran J, Capon DJ. Functionally distinct G proteins selectively couple different receptors to PI hydrolysis in the same cell. Cell. 56: 487-93. PMID 2492452 DOI: 10.1016/0092-8674(89)90251-1  1
1988 Ashkenazi A, Peralta EG, Winslow JW, Ramachandran J, Capon DJ. Functional role of muscarinic acetylcholine receptor subtype diversity. Cold Spring Harbor Symposia On Quantitative Biology. 53: 263-72. PMID 3254774 DOI: 10.1101/Sqb.1988.053.01.033  1
1988 Leibovitz E, Ashkenazi A, Levin S, Nissim F. Fatal pericardial tamponade complicating total parenteral nutrition via a silastic central vein catheter. Journal of Pediatric Gastroenterology and Nutrition. 7: 306-7. PMID 3127571  1
1988 Peralta EG, Winslow JW, Ashkenazi A, Smith DH, Ramachandran J, Capon DJ. Structural basis of muscarinic acetylcholine receptor subtype diversity. Trends in Pharmacological Sciences. 6-11. PMID 3074539  1
1988 Peralta EG, Ashkenazi A, Winslow JW, Ramachandran J, Capon DJ. Differential regulation of PI hydrolysis and adenylyl cyclase by muscarinic receptor subtypes. Nature. 334: 434-7. PMID 2841607 DOI: 10.1038/334434A0  1
1988 Pines M, Ashkenazi A, Cohen-Chapnik N, Binder L, Gertler A. Inhibition of the proliferation of Nb2 cells by femtomolar concentrations of cholera toxin and partial reversal of the effect by 12-O-tetradecanoyl-phorbol-13-acetate. Journal of Cellular Biochemistry. 37: 119-29. PMID 2839525 DOI: 10.1002/jcb.240370111  1
1987 Ashkenazi A, Cohen R, Gertler A. Characterization of lactogen receptors in lactogenic hormone-dependent and independent NB2 lymphoma cell lines. Febs Letters. 210: 51-5. PMID 3803581 DOI: 10.1016/0014-5793(87)81296-6  1
1987 Kohl D, Ashkenazi A, Ben-Shaul Y, Bacher A. Tight junctions of jejunal surface and crypt cells in celiac disease: a freeze-fracture study. Journal of Pediatric Gastroenterology and Nutrition. 6: 57-65. PMID 3794934  1
1987 Ashkenazi A, Vogel T, Barash I, Hadari D, Levanon A, Gorecki M, Gertler A. Comparative study of in vitro and in vivo modulation of lactogenic and somatotropic receptors by native human growth hormone and its modified analog prepared by recombinant deoxyribonucleic acid technology. Endocrinology. 121: 414-9. PMID 3595523 DOI: 10.1210/endo-121-1-414  1
1987 Ashkenazi A, Madar Z, Gertler A. Partial purification and characterization of bovine mammary gland prolactin receptor. Molecular and Cellular Endocrinology. 50: 79-87. PMID 3582727 DOI: 10.1016/0303-7207(87)90079-7  1
1987 Cohen R, Ashkenazi A, Elberg G, Gertler A. A comparative study of lactogenic hormone binding sites in the adrenal gland, ovary and kidney of the lactating cow. Journal of Receptor Research. 7: 921-36. PMID 3450875 DOI: 10.3109/10799898709054570  0.01
1987 Peralta EG, Ashkenazi A, Winslow JW, Smith DH, Ramachandran J, Capon DJ. Distinct primary structures, ligand-binding properties and tissue-specific expression of four human muscarinic acetylcholine receptors. The Embo Journal. 6: 3923-9. PMID 3443095 DOI: 10.1002/J.1460-2075.1987.Tb02733.X  1
1987 Peralta EG, Winslow JW, Peterson GL, Smith DH, Ashkenazi A, Ramachandran J, Schimerlik MI, Capon DJ. Primary structure and biochemical properties of an M2 muscarinic receptor. Science (New York, N.Y.). 236: 600-5. PMID 3107123 DOI: 10.1126/Science.3107123  1
1987 Ashkenazi A, Pines M, Gertler A. Down-regulation of lactogenic hormone receptors in Nb2 lymphoma cells by cholera toxin. Biochemistry International. 14: 1065-72. PMID 2839183  1
1987 Ashkenazi A, Winslow JW, Peralta EG, Peterson GL, Schimerlik MI, Capon DJ, Ramachandran J. An M2 muscarinic receptor subtype coupled to both adenylyl cyclase and phosphoinositide turnover. Science (New York, N.Y.). 238: 672-5. PMID 2823384 DOI: 10.1126/Science.2823384  1
1986 Ashkenazi A, Zaizov R, Matoth Y. Effect of splenectomy on destructive bone changes in children with chronic (Type I) Gaucher disease. European Journal of Pediatrics. 145: 138-41. PMID 3732318  0.01
1986 Wieser H, Belitz HD, Idar D, Ashkenazi A. Coeliac activity of the gliadin peptides CT-1 and CT-2. Zeitschrift Fã¼R Lebensmittel-Untersuchung Und -Forschung. 182: 115-7. PMID 3705771  1
1986 Gertler A, Shamay A, Cohen N, Ashkenazi A, Friesen HG, Levanon A, Gorecki M, Aviv H, Hadary D, Vogel T. Inhibition of lactogenic activities of ovine prolactin and human growth hormone (hGH) by a novel form of a modified recombinant hGH. Endocrinology. 118: 720-6. PMID 2417826 DOI: 10.1210/endo-118-2-720  1
1985 Dick J, Ashkenazi A, Chamke M. [Oculo-cerebro-renal syndrome in a newborn]. Harefuah. 108: 592-3. PMID 4065726  0.01
1984 Ashkenazi A, Idar D, Maimon M, Hegesh E, Frank E, Hahn T, Wolman Y, Levin S. Alkaline phosphatase activity in fresh intestinal mucosa and cultured mucosal explants. Journal of Pediatric Gastroenterology and Nutrition. 3: 210-4. PMID 6707840  1
1984 Ashkenazi AI. [Traumatic arthritis of the wrist joint]. Khirurgiia. 58-62. PMID 6700172  0.01
1984 Dahan S, Slater PE, Cooper M, Brautbar C, Ashkenazi A. Coeliac disease in the Rehovot-Ashdod region of Israel: incidence and ethnic distribution. Journal of Epidemiology and Community Health. 38: 58-60. PMID 6608573  1
1984 Ashkenazi A, Frydman M, Weitz R, Lehrer E, Zahavi I. Myocarditis and acute infantile hemiparesis. Case report. Helvetica Paediatrica Acta. 39: 491-5. PMID 6543858  1
1984 Wieser H, Belitz HD, Ashkenazi A. Amino-acid sequence of the coeliac active gliadin peptide B 3142. Zeitschrift Fã¼R Lebensmittel-Untersuchung Und -Forschung. 179: 371-6. PMID 6524078  1
1984 Ashkenazi AI, Lipkin SI. [So-called "calcium gout"]. Khirurgiia. 107-11. PMID 6521289  0.01
1984 Gertler A, Ashkenazi A, Madar Z. Binding sites of human growth hormone and ovine and bovine prolactins in the mammary gland and the liver of lactating dairy cow. Molecular and Cellular Endocrinology. 34: 51-7. PMID 6321275 DOI: 10.1016/0303-7207(84)90158-8  1
1983 Zlotogora J, Ben Ezra D, Livni N, Ashkenazi A, Cohen T. A muscle disorder as presenting symptom in a child with mucolipidosis IV. Neuropediatrics. 14: 104-5. PMID 6877526 DOI: 10.1055/s-2008-1059563  1
1983 Ashkenazi A, Cooper M, Nissim F, Dahan S, Garti R, Levin S. Occurrence of celiac disease in children in a defined area of Israel. Israel Journal of Medical Sciences. 19: 63-6. PMID 6832950  1
1983 Wieser H, Belitz HD, Ashkenazi A, Idar D. Isolation of coeliac active peptide fractions from gliadin. Zeitschrift Fã¼R Lebensmittel-Untersuchung Und -Forschung. 176: 85-94. PMID 6405556  1
1982 Ashkenazi AI. [Late results of surgical treatment of Kienboeck's disease]. Khirurgiia. 43-7. PMID 7176401  0.01
1982 Souroujon M, Ashkenazi A, Lupo M, Levin S, Hegesh E. Serum ferritin levels in celiac disease. American Journal of Clinical Pathology. 77: 82-6. PMID 7055099  1
1982 Wieser H, Springer G, Belitz HD, Ashkenazi A, Idar D. Toxicity of different wheat gliadins in coeliac disease. Zeitschrift Fã¼R Lebensmittel-Untersuchung Und -Forschung. 175: 321-6. PMID 6758408  1
1982 Ashkenazi A, Levin S, Idar D, Handzel ZT, Altman Y, Or A, Barzilai N. Cellular immunity in children with coeliac disease. European Journal of Pediatrics. 138: 250-3. PMID 6749506 DOI: 10.1007/BF00441211  1
1981 Brautbar C, Freier S, Ashkenazi A, Dekelbaum R, Tur-Kaspa I, Amar A, Cohen I, Sharon R, Abecassis R, Levene C, Cohen T, Albert E. Histocompatibility determinants in Israeli Jewish patients with coeliac disease: population and family study. Tissue Antigens. 17: 313-22. PMID 6947507  1
1981 Ashkenazi A, Levin S, Idar D. Immunological assays for coeliac disease. Lancet. 2: 687. PMID 6116058  1
1981 Ashkenazi A, Levin S, Idar D, Or A, Barzilai N, Handzel ZT. Effect of gluten-free diet on an immunological assay for coeliac disease. Lancet. 1: 914-6. PMID 6112326  1
1980 Ashkenazi A, Levin S, Miskin A. Immunoglobulin levels in children with celiac disease: variations with age and diet. Israel Journal of Medical Sciences. 16: 843-6. PMID 7451111  1
1980 Ashkenazi A, Levin S, Idar D, Or A, Rosenberg I, Handzel ZT. In vitro cell-mediated immunologic assay for cow's milk allergy. Pediatrics. 66: 399-402. PMID 6999447  1
1980 Ashkenazi A, Levin S, Idar D, Or A, Rosenberg I, Handzel ZT. Immunological assay for the diagnosis of coeliac disease: interaction between purified gluten fractions. Pediatric Research. 14: 776-8. PMID 6992088 DOI: 10.1203/00006450-198005000-00013  1
1980 Ashkenazi A, Levin S, Krasilowsky D. Gluten and autism. Lancet. 1: 157. PMID 6101497  1
1979 Ashkenazi A, Berrebi A, Levi R, Sakal E, Idar D. Frequency of HLA-B8 in Israeli children with celiac disease. Israel Journal of Medical Sciences. 15: 826-8. PMID 521261  1
1979 Ashkenazi A, Krasilowsky D, Levin S, Idar D, Kalian M, Or A, Ginat Y, Halperin B. Immunologic reaction of psychotic patients to fractions of gluten. The American Journal of Psychiatry. 136: 1306-9. PMID 384809  1
1979 Hahn T, Levin S, Handzel ZT, Ashkenazi A, Chemke J, Shterk V. An apparently immunoregulatory effect of human leukocyte interferon on the blastogenic response in Down's syndrome. Israel Journal of Medical Sciences. 15: 775-8. PMID 159876  1
1978 Ashkenazi AI, Arenberg AA, Korolev AP. [Surgical treatment of Dupuytren's contracture by the method of "open palm and fingers"]. Khirurgiia. 22-7. PMID 732108  0.01
1978 Ashkenazi A, Idar D, Handzel ZT, Ofarim M, Levin S. An in-vitro immunological assay for diagnosis of coeliac disease. Lancet. 1: 627-9. PMID 76167  1
1977 Handzel ZT, Levin S, Ashkenazi A, Hahn T, Altman Y, Czernobilsky B, Shechter B, Trainin N. Immune deficiency of T system with possible T cell regulatory activity defect. Israel Journal of Medical Sciences. 13: 347-53. PMID 194869  1
Show low-probability matches.